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ABSTRACT 
The action of the hypoglycemi.c compounds, tolbutamide 
and phenethylbiguanlde, on protein biosynthesis was investigated 
by the use of rat liver homogenates, the necessary cofactors and 
1euc1ne-c14. The results show that the incorporation of leuclne-
C14 into he~atic protein is inhibited by both compounds, though 
in a strikingly different manner. The inhibition by tolbutamide 
is linear with respect to concentration whereas the inhibition by 
phenethylbiguanide is not evident until a certain concentration 
is reached. At this pOint, the amount of incorporation decreases 
markedly until it levels off at a very low value. It has been 
postulated that there 1s some substance present which combines 
with phenethylblguanide and renders it inactive toward inhibition 
of protein synthesis. Glucose was investigated in tnis respect 
and found to have no effect on either tolbutamide or phenethyl-
biguanide induced inhibition. 
The catabolism of leucine was measured by the amount of 
C1402 liberated in the course of the incubation. Both tolbutamide 
and phenethylbiguanide were found to inhibit CO2 production. 
Again, inhibition by tolbutamld.,3 was linear with respect to con-
centration. Phenethylbiguanld:a caused a pronounced initial inhi-
bition which tended to level off near the same concentration where 
the protein inhibition first occurs. This suggests that one of 
the reasons that low concentrations of PESO does not inhibit pro-
tein incorporation is due to the great decrease in leucine catab-
olism. Since less leucine is broKen down (catabolized), there is 
ecessarily more present to be incorporated into the protein. 
ccording to this postulation, the initial great decrease in leu-
cine catabolism compensates for the inhibition 1n protein anabo-
ism. Once the inhibition of protein catabolism has levelled off, 
the inhibition of lncorporatlon by added PEBG becomes evident. 
The results found are exactly opposite those reported 
by Krahl (14) for insulin. Whereas tolbutamide and phenethyl-
biguanide inhioi t protein synthesis i!l ',o'i tro, insulin accelerates 
it. Moreover, while the accelerating action of insulin is depen-
ent on the presence of' glucose in the medhun;thc= innibi tory ac-
of the oral hypoglycemic agents is totally unresponsive to 
he addition of glucose. 
These results suggest that the oral hypoglycemic agents 
studied, although very proficient at lowering blood sugar, do not 
ossess all the other attributes of insulin. They cannot aid the 
egative protein balance associated with diabetes; they may, in 
act, due to their inhibitory effects, aggravate the condition. 
___ ~mD_' __________________________________________________________ -' 
CHAPTER I 
DIABETES AND THE ACTION OF INSULIN 
Historl 
A reference in the ancient Papyrus Ebers (105) to a con 
dition that may have been diabetes mellitus is indefinite, but it 
does suggest that a written record of the disease may be dated as 
far baok as 1500 B.C. Whether or not this is true, a good clini-
oal description was given by Celsus (30 B.C. to 50 A.D.). It was 
however, another Roman, Aretaeus of Cappadocia (30 A.D. to 90 A.D. 
who oOined the term "diabetes" meaning literally "to pass through" 
The name derives from the faot that it was considered 
ease of the kidney beoause of the polyuria. 
The glycosuria associated with diabetes is not mentione 
in the European literature on the subject until the seventeenth 
century, but it was described very completely by the Arab physi-
cian Avicenna about the year 1000 A.D. Even before this time, 
Chinese, Japanese and Hindu writings indicate that a disease asso-
ciated with a sweet urine was known to these people. 
Thomas Willis (142) was the first European to recognize 
the glycosuria assooiated with diabetes. This opened the door to 
innumerable observations on the subJect. Cawley in 1'788 was ap-
1 
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parently the first to associate diabetes with the pancreas. He 
found multiple caliculi and destruction of pancreatiC tissue at 
the autopsy of a patient who had died of diabetes (140). 
In the nineteenth century~ the contributions of Claude 
Bernard in the field of carbohydrate metabolism stand out. He 
established the presence of glycogen in the liver and propounded 
the theory of sugar formation from glycogen. He failed to recog-
nize the role that the pancreas plays in controlling carbohydrate 
metabolism~ but he did theorize that the high blood sugar levels 
found in diabetes were due to an overproduction of sugar by the 
liver (11). 
In 1869.~ Paul Langerhans discovered the islets in pan-
creatic tissue that were named in his honor by Laguesse. 
Langerhans did not appreciate the physiological significance of 
the islets and considered them to be lymph glands (77). In 1889~ 
von Mering and Minkowski showed that totally depancreatized dogs 
developed hyperglycemia~ glycosuria, and finally died in ketosis 
and coma (98). This was the first definite experimental proof 
that diabetes may be of pancreatic origin. Attempts by Minkowski 
to prepare a pancreatic extract which would have a hypoglycemic 
act1vity failed. This major advancement was due to the work of 
Banting and Best (8J9~lO). Using pancreatic extracts made by 
procedures designed to prevent the action of proteolytic enzymes, 
i.e., utilizing cold acid and alcohol, they demonstrated an 
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extensive lowering of blood and urine sugar in seventy-five con-
secutive tests in ten different depancreatized dogs. The first 
crystalline insulin was prepared by Abel of Johns Hopkins in 1926, 
(1). Mention must be made here of the monumental chemistry per-
formed by Sanger and his co-workers in elucidating the structure 
of insulin (117). 
Research along other lines continued unabated. Houssay 
established the hypersensitivity of hypophysectomized toads and 
dogs to insulin and proved for the first time that experimental 
diabetes produced by total extirpation of the pancreas can be a-
meliorated by hypophysectomy (59). The first practical oral hypo-
glycemic agent, l-butyl 3-sulfonylurea (also called carbutamide) 
was reported in 1955 by Franke, Achelis Betram ~!!. (2,14,45). 
Although it was soon found to be toxic and was withdrawn from 
clinical use in the United States, it is the parent compound whic 
led to the discovery of the highly successful arylsulfonylureas. 
Recent research has been directed toward elucidating the 
mechanism by which insulin acts. So much work has been performed 
on this phase that it is impossible to enumerate individual inves-
tigators. 
CARBOHYDRATE METABOLISM 
The primary metabolic defect in diabetes is Ia failure 0 
4 
aberration in the metabolism of carbohydrate. This is obvious 
from the high blood glucose concentration. There can be no doubt 
that insulin is concerned with an early stage of the metabolism 
of glucose, but whether or not this is its sole action, and the 
mechanism by which it is achieved, are still matters for discus-
sion and experimentation. The first reaction of glucose in mam-
malian tissue and one necessary for its further metabolism is the 
formation of glucose -6-phosphate through the action of gluco-
kinase. This reaction has long been regarded as a site of hormo-
nal regulation, including acceleration by insulin. There are two 
ways in which an acceleration by insulin can be accomplished; 
(1) by increasing the rate of entry of glucose into the cell 
through the cell membrane and (2) by increasing the rate of forma-
tion of glucose-6-phosphate by direct action on the enzyme hexo-
kinase. 
The first hypotheSiS as propounded by Levine (80) is 
based on the observation that insulin greatly enhances the uptake 
of glucose by extrahepatic tissues at all levels of blood glucose. 
This was tested using galactose, which will enter cells, but Is 
not metabolized to any extent except in the liver, kidney and in-
testine. Levine and Goldstein ('79) surgically removed the liver, 
kidney and intestine from a dog. A test dose of galactose was 
injected and the blood concentration determined. After this, in-
sulin was given and it was observed that the blood galactose 
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level dropped appreciably. This was taken to indicate that the 
insulin permitted the galactose to leave the extra cellular com-
partment. penetrate the cell wall and enter the intracellular 
compartment. 
The second hypothesis has no direct evidence to support 
it, but it cannot be overlooked as a possibility (140). It is 
mentioned here primarily for the sake of completeness. 
LIPID METABOLISM: 
In the condition of diabetes mellitus there are present 
four principal abnormalities in lipid metabolism. 
1. blockage in fatty acid synthesis 
2. increase in fatty acid oxidation 
3. development of ketOSiS 
4. increase in cholesterol synthesis n I Each of these topics will be discussed briefly in turn. ~ 
The first convincing evidence that the diabetic pos-
sessed an impaired ability to synthesize fat was obtained by 
Stetten and Boxer (121) when they demonstrated that the Incorpora 
tion of deuterium-labeled water into fatty acids was greatly de-
---
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pressed in the intact diabetic rat. This finding was readily con-
firmed with C14 labelled glucose both in ::solated liver slices of 
alloxan diabetic rats and in intact animals (26). 
The site of this defect in lipogenesis in the metabolic 
scheme is difficult to locate. The reduction could be due to met-
abolic blocks at any of numerous biochemical steps involved in 
glycolysis and lipogenesis. In fact, tIle possible site of insulin 
actIon at the entrance of glucose into the cell or in its conver-
sion to glucose-6-phosphate should of itself result in a decrease 
in fat synthesis from glucose. It should be mentioned that the 
dIabetic block in lipogenesis has been shown to be much more se-
vere than the block in glucose oxidation, a finding which suggests 
that the latter defect is not the direct and only cause of the in-
ability to convert glucose to fatty acid. The studies of Chernick 
and Chaikoff (30) have demonstrated that in diabetic liver the 
~synthesis of fat from fructose _C14, as well as from glucose-C14~ 
is greatly depressed. 
The consequences of this disturbance have been most dra-
matically shown by the experiment of Drury (37) in Which diabetic 
rats or dogs subjected to alternate days of fasting and feeding 
suffered marked weight loss in the course of only one week of such 
treatment. Normal animals maintained their body weights on this 
programj likewise, diabetic rats when fed daily did not lose 
weight. It seems apparent that the inability of these animals to 
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store carbohydrate, even for a period of one day is a direct re-
sult of their inability to synthesize fatty acids, and it 1s evi-
dent that under these circumstances lipogenesis is a function 
without which the diabetic animal cannot survive. 
II. Fatty Acid Oxidation 
POI' a long time there has been suggestive eVidence that 
in the diabetic, the rate of fatty acid oxidation is increased 
above normal. The total amount of carbon dioxide produced by the 
diabetic as measured by the basal metabolic rate tends to be nor-
mal or even increased (140). 
It is evident that, since glucose utilization is reduce4 
an increased oxidation of fat and to a lesser extent of protein 
must take place to yield this carbon dioxide and the necessary 
,metabolic energy. More direct eVidence for this increased rate of 
M ~breakdown of fat in diabetes has been obtained by Lossow and co-
~ 
workers (85). By observing the metabolism of C14_ labeled tri-
palmitin in diabetic and normal rats, he demonstrated that the 
diabetic oxidizes fatty acids to carbon dioxide at a rate consid-
erably above the normal. Further, this increased oxidation of fat 
seems clearly to be due to the decreased amount of glucose under-
going oxidation, Since the injection of glucose in normal animals, 
or the administration of insulin to the diabetic results in a 
8 
prompt depression of fatty acid oxidation. 
III. Diabetic Ketosis 
The factors leading to diabetic ketosis may be summa-
rized as follows. The inability of the diabetic to utilize ade-
quate amounts of glucose makes it necessary to rely on increased 
fat oxidation for energy. Fat can provide ample amounts of acetyl 
CoA but can supply neither pyruvate nor NADPH. As a result, the 
Krebs cycle is unable to maintain its integrity, and acetyl CoA 
can be oxidized to carbon dioxide only after the concentration of 
this compound is sufficiently high (54) (46). The lack of NADPH 
prevents this excess acetyl CoA from being converted into fatty 
acids, as would normally occur under these Circumstances, and the 
accumulated acetyl CoA 1s thereby shunted into HMO CoA and hence 
R into the syntheSiS of ketone bodies. 
2 , 
IV. Cholesterol Synthesis 
Liebow and Hellerstein (81) have compiled data from lit .. 
erature on diabetes. It shows conclusively that a d~finite in-
crease in severity and incidence of atherosclerosis l:lccompanies 
the disease. It has been observed by Castiglioni (2~) that hyper-
cholesterolemia very frequently accompanies diabetes Finally, 
there has been a great deal of work done implicating atherosclero-
9 
sis with blood cr:.olesterol level;;:;. Early studies by Wj ndalls (143) 
and Schonhejmer (120) indicated that in atherosclerotic aortas~ 
th'; cholesterol co~tent was greater than in normal ones. A weal t 
of statistical evidence relating atherosclerosis to cholesterol 
has been summed u? by Rosenthal (113). 
It has been directly shown 1Q vitro that the livers of 
diabetic rats can synthesize cholesterol at increased rates. Thi 
was demonstrated by Hotta and Chaikoff (58) by measuring choles-
terol after incubation of the liver slice with acetate-C14• The 
mechanism of this increase is not clear at the present time. 
Thus, two major medical problems atherosclerosis and 
diabetes, currently confronting the scientific world are seen to 
be intimately related. The mass of evidence demonstrating a 
marked incidence and severity of atherosclerosis in diabetes is 
incontrovertible. Provided they have the disease long enough, 
I.; diabetics will almost invariably be atherosclel~otic. Warren (133) 
I has found only four patients free of atherosclerosis among 484 
autopsied cases with diabetes for five years or longer. This uni 
versality of atherosclerosis in diabetes is true for young or old, 
male or female. Joslin (69) has stressed that the frequency and 
severity of atherosclerosis in diabetes is correlated with long 
standing uncontrolled glycosuria and hyperglycemia, with concomi-
tant hyperlipemia and hypercholesterolemia. 
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PROTEIN METABOLISM 
I. Effects of insulin on protein metabolism in intact animals: 
There is a wide range of conflicting reports in the lit 
erature concerning the effects of insulin on the growth of ani-
mals. Some of the conclusions are invalid because they were per-
formed on fasting animals. There seems to be complete agreement 
that the administration of insulin does not cause demonstrable 
protein anabolism in the fasting animal (15)47J50,125). There is 
conclUSive evidence that in the non-fasting animal, or in man, in 
sulin tends to cause protein anabolism as indicated by a positive 
nitrogen balance (67,71,90,125). However) this tendency of insu-
lin to produce a positive nitrogen balanoe has not led to growth 
in normal animals (41,62,63). The principal experimental results 
of the influence of insulin on protein metabolism may be summa-
~ rized in Table I J modified from Lukens (88). I II. Effects of insulin on protein metabolism in isolated tissues: 
A. Muscle: It has been demonstrated by Krahl (73) and Sinex ~ 
ale (123) that the incorporation of 014_ glycine or 014.alanine 
into protein of diaphragms from fed rats was enhanced by insulin 
in the absence of glucose in the incubation medium. The order of 
magnitude of the stimulation was as great as 40%. This appears 
to indicate that the stimulation of amino acid incorporation by 
insulin into muscle occurs by a mechanism other than the stimula-
TABLE I 
STUDIES OF THE INFLUENCE OF INSULIN 
ON PROTEIN METABOLISM 
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I. Pancreatectomy results in an increased catabolism of endoge-
nous protein as evidenced by an increased nitrogen excretion 
during fasting (97). 
Insulin treatment of the depancreatectomized animal, or of the 
severely diabetic patient prevents this acceleration of pro-
tein catabolism (7,27,40,78,125). 
From in vivo studies on the disposal of N15 - glycine, there 
is some evidence that protein synthesis is defective and pro-
teinbreakdown excessive in the diabetic animal (5'r). 
II. Insulin given to normal animals: 
A. Investigators who failed to observe protein anabolism: 
1. No increased growth of rabbits (84). 
2. No effect on fasting nitrogen balance in rats (15). 
3. No effect on growth or nitrogen excretion of normal 
rats with or without control of diet (50). 
4. No change in nitrogen excretion (65). 
5. No effect on growth of rats (41,62,63). 
B. Investigators who concluded that insulin promotes protein 
anabolism: 
1. Glucose and insulin spare more protein than glucose 
alone in normal subjects (67). 
2. Insulin causes positive nitrogen balance in fed 
normal dogs (125). 
3. Insulin causes nitrogen retention in normal rats, wit 
or without constant diet (90). 
4. There is seen a positive nitrogen balance in patients 
given insulin (71). 
5. Liver and diaphragm incorporate more labeled amino 
acid under influence of insu11n 1f glucose 1s present (72) • 
12 
tion of' glucose transport. 
B. Liver: The work on amino acid incorporation in liver slices 
has been performed by Krahl (14). He reported that the capacity 
of liver slices to incorporate glYCine-cl4 into glutathione or 
protein was impaired in liver slices from alloxan-diabetic rats, 
the degree of the defect increasing in proportion to the duration 
and severity of the diabetes. No direct ~ vitro effect of insu-
lin could be demonstrated with slices from the most severely dia-
betic animals, although restoration of normal incorporation could 
be achieved by the injection of insulin into the animal ten hours 
or more before the start of the experiment. 
The situation with slices from mildly diabetic rats was 
quite different: insulin added ~ vitro raised the incorporation 
of glycine-C14 into glutathione or protein if glucose was also 
presentj glucose alone had a slight effect, insulin alone had none 
These experiments were repeated by Krahl and Penhos (75) 
using liver slices from both normal and partially depancreatized 
rats at various times after pancreas removal. The results fully 
confirmed and extended the earlier work in showing, first, that 
insulin stimulated amino acid incorporation into liver protein 
when added ~ vitro; second, that the effect (for liver slices 
from fasting animals) depends on the presence of glucose; third, 
,that the stimulation is greater with slices from mildly insulin 
deficient animals than with those from either normal animals or 
13 
long term diabetic animalsj and fourth, that this ~ vitro effect 
of insulin requires about two or three hours to become maximal. 
It is apparent that the action of insulin on protein 
metabolism is profoundly different in liver and muscle. Whereas 
the stimulation of incorporation evidenced is dependent on the 
presence of glucose in the liver l it is independent of glucose 
concentration in muscle. This suggests a different mode of actio 
in the two tissues. 
DISCUSSION 
The various metabolic defects found in diabetes mellitus 
have been discussed at some length. That the secondary effects 
are important is seen from the statistic that more diabetics die 
from coronary heart disease due to atherosclerosis than from the 
actual diabetes itself. This is turn is related to the accompa-
nying disturbances in lipid metabolism rather than to the so 
called "primary" disturbance in carbohydrate metabolism. If dia-
betes mellitus is to be succeSSfully controlled, all of the accom-
panying metabolic disorders must be taken into account. It is 
obviously not sufficient that a substance merely lower the blood 
sugar level for it to be useful in the treatment of the diseasej 
it must also treat the accompanying metabolic derangements of 
lipid and protein metabolism. 
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Since diabetes is due to a lack or at least a reduction 
of native insulin, it is apparent that an increase in insulin 
should relieve all the symptoms of diabetes. Such has been found 
to be the case. When insulin is administered to the diabetic, the 
blood sugar is lowered, the cholesterol in the blood is reduced, 
ketonemia and ketonuria are abolishedj in short, all the diabetic 
manifestations disappear. 
Recently, a number of oral hypoglycemic compounds have 
been introduced for the treatment of diabetes mellitus. These 
have done an admirable job in the reduction of the blood sugar 
level. They have not been investigated very thoroughly in respeot 
to their effect on the other metabolic disorders concerned with 
diabetes. 
Greenberg and associates (53) have reported an increase 
in the level of plasma beta lIpoproteins of diabetics when switch-
I ~ed from insulin therapy to an oral hypoglycemic agent (tolbutamid 
IThey interpret this as possibly indicating that the oral hypo-
glycemic agent does not control the entire diabetic state as ade-
quately as does insulin. 
On the other hand, it has been conclusively demonstrated 
by McDonald and Dalidowicz (95) that the presence of tolbutamide 
(and several other oral hypoglycemic agents) effectively reduce 
the ~ vitro synthesis of cholesterol from acetate and mevalonate 
15 
by rat liver homogenates. This would indicate that the oral hypo-
glycemic agents should be effective in reducing the hypercholes-
terolemia which accompanies diabetes. 
This investigation into the relationship between the 
oral hypoglycemic agents and protein synthesis is meant to further 
. clarify the role of those compounds in the treatment of diabetes 
mellitus. 
-CHAPTER II 
THE CHEMISTRY OF INSULIN AND THE ORAL HYPOGLYCEMIC AGENTS 
INSULIN 
Insulin has been shown to be a protein consisting of two 
polypeptide chains. The arrangement of amino acids as finally 
established by Sanger and his co-workers is given in Figure I. 
The A chain contains 21 amino acids} with glycine at the amino, 
and asparagine at the carboxyl, end. The B chain has 30 amino 
acids with phenylalanine at the amino end and alanine at the other. 
The two chains are Joined together by -S-S- linkages at Al-B'r and 
A20-Bl9. There is also a disulfide bridge from A6 to All, forming 
a ring. The amino acide at AS,9,lO can be varied in insulin of 
,various species without demonstrable differences in physiological 
activity (115,116,117). 
DELETION OF AMINO ACIDS 
Harris and Li (55) subjected insulin to digestion for 
six hours with carboxypeptidase. They found that 1.9 moles of 
alanine and 0.4 moles of asparagine, per 12,000 gmt insulin, had 
been removed with retention of about 80 per cent of the biological 
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FIGURE I 
THE STRUCTURE OF INSULIN 
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activity. Further, with mild trypsin treatment a large fraction 
of the terminal alanine could be hydrolysed off under conditions 
where Van Abeele and Campbell (14,() reported no loss of biological 
potency. Harris and Li concluded that the C-terminal alanine in 
the B chain was not necessary for full biological activity, but 
that the C-terminal asparagine of the A chain probably was. 
Smith et ale (124) treated insulin with leucine amino-
peptidase which can attack the insulin structure only at the amino 
ends of the chains. From this work, it was concluded that the 
amino acids Ea-B6 were not necessary for full hormonal activity. 
However, the removal of AI-A5 probably leads to some loss of ac-
tivity. 
From the preceding diSCUSSion, it is apparent that the 
entire insulin molecule is unnecessary for hormonal activity. 
Exactly how much can be removed while still maintaining physiolog-
I ical actionJ has not been determined. Such knowledge may yield valuable insight into the mode of action of the hormone. 
The actions of the hormone have been treated in the 
first chapter and will not be reiterated here. Some other exper-
imental findings pertinent to the structure of insulin will be 
briefly mentioned. 
Insulin has been labeled by esterification of the ali-
phatic hydroxyl groups With 335°4, (48) by iodination of one or 
more tyrosine residues with I131 J (43) and by tritiation (149). 
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The products have not been separated into pure components. This, 
together with the small number of animals used in assaying the 
residual biological activity makes it impossible to decide whethe 
the labeled molecules retain biological activity. 
The three dimensional structure of insulin in the solid 
state has been accounted for (82) by assuming that the A and B 
chains are helices held together by the two disulfide bonds. 
Each two helices of the 6000 molecular weight structure are then 
considered to be bonded with two others into a 12,000 molecular 
weight unit via a zinc ion bridging the BlO and BIO' histidine 
reSidues of the two sub-units. 
The thI'ee dimensional structure of insulin in solution 
depends on a number of factors: the concentration of insulin, the 
pH, the ionic strength, and the dielectric constant of the medium. 
In the physiological pH range, molecular (particle) weight values 
of 24,000 to 48,000 have been estimated (36, 104). 
THE ORAL HYPOGLYCEMIC AGENTS 
HISTORY 
Since insulin is a protein hormone, it is attacked by 
proteolytic enzymes present in the digestive system with a subse-
quent loss of activity. It is for this reason that insulin must 
be injected if it i8 to be beneficial. Since the disadvantages 
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0:1' injection were readily apparent, a search for hypoglycemic com-
pound a which could be administered orally has long been in effect. 
As early as 1926, Frank, Nothman, and Wagner (45) reported a hypo-
glycemic effect 01' a biguanide J synthalin. Further study of this 
compound by Graham and Linder (52) revealed that it caused severe 
liver damage, and it was soon abandoned as a possible insulin sub-
stitute. 
For a long tlms, the extracts of a number of plants have 
been used in many parts of the world as a treatment for diabetes 
mellitus with varying degrees of success. In connection with 
this, Allan (3) investigated the extralJt of the blueberry leaf am 
Hugh-Jones (61) studied the extracts of periwinkle, mistletoe, and 
nlckerberry. The alkalOid, galepine" was described by Muller (102 
to have the propeI'ty of reducing the blood sugar of both normal 
and diabetic men. Clementi (31) ascribes Similar properties to 
another alkaloid obtained from plants, lapanine. A wide range of 
natural sources have yielded compounds with hypoglycemic proper-
ties. Collip (32) extracted a substance, glucokinen, from clams. 
This compound produoed a marked hypoglycemic effect when injected 
into rabbits. Similarly, Little, Levine and Best (83) d1scovered 
an insulin mimetic agent in the diSintegration products of k1lled 
bacteria. Most of these extracts caused l1ver damage, which fact 
may account for the1r hypoglycemic effect. At any rate, they are 
useless as therapeutic agents. 
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Hassal~ Reyle, and Fing (56) isolated a hypoglycemic 
compound, which tbey called Hypoglycin A; from the fruit of a 
plant J BliQhia sapida. Anderson et ale (4) and Ellington, Hassal, 
and Plimmer (38) determined that the hypoglycemic activity was du 
to an unusual amino acid whose structure is given in Table III. 
A second hypoglycemic compound has been isolated from the same 
source and designated Hypoglycin B. It is a dipeptide composed 
of Hypoglycin A and glutamic acid (56). 
In 1942, the I'esearch on oral hypoglycemic compounds in 
tensified when Janbon .. Chaptal, Vadel, and Schaap (66) discovered 
that a synthetic compound, 5-isopropyl-2-sulfanilamide-l,3,4-thia 
diazole (IPTD) could lower blood sugar levels. Although this par 
ticular compound proved to be toxic to the point of fatality, its 
discovery served to open an era of research on synthetic oral hy-
poglycemic agents. Since then a wide variety of compounds have 
been examined for hypoglycemic action. 
In the next four years, Loubatieres (86) studied the 
mode of action of IPTD and other thiadiazoles in dogs and rabbits. 
He discovered that IPTD fails to produce hypoglycemia if the en-
tire pancreas is removed, but may do so if as little as one-sixth 
of the gland remains. It appears, therefore, that this substance 
is not a substitute for insulin but rather enhances the effect of 
native insulin already present, or else spurs the beta cells to a 
greater production of insulin. Loubatieres found that IPTD is 
c=c 
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Carbutamide 
Tolbutamide 
Chlorpropamide 
Metahexamide 
Acetohexamide 
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TABLE III 
GUANIDINE AND SOME DERIVATIVES 
(CH2 ) 2 NHCNHC~ 
\l " NH NH 
Guanidine 
Syntha1in A 
(n .. 10) 
Synthalln B 
(n ... 12) 
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Phenethy1blguanide 
Hypog1ycln A 
Hypog1ycln B 
IPTD 
most effective when 1n.]ected directly into the pancreatic artery 
and that .1 t acts independently of tYte nervous system. It also 
lowers the blood sugar in inverse proportion to the sulfonamide 
level of the blood l and raises the respiratory quotient after glu-
cose administration. Chen .. Anderson, and Maze (29) have reported 
a hypoglycemic action of 5-cyclopropyl-2-sul,fanilamlde-l .. 3,,4-thia.-
diazole in intact rabbits. However .. s.ince the thiadiazoles were 
very toxic they were never put to clinical use. 
About tl1is time.1 the studies of F'ranke J Acnells, Betram 
~!!.. (2,14,44) on a new hypoglycemic compound, I-butyl-3-sulfo-
nylurea (carbutamide) created stIll more interest in tile field. 
Aga1n" this compound was found to be toxic and was withdrawn from 
clinical use, at least in the United States. Since then literally 
thousands of related cOilpounds bave been studied for tneir hypo-
glycemic activity (24.194). 
Most of the compounds tested were found to be too toxic 
for human consumpt1on.. but three analogues of' carbutamlde, namely 
tolbutamide, chlorpropamide" and metahexamide have been subjected 
to clinical studies and the first two are currently extensively 
used 1n the management of mild, adult d1abetes mellitus. The pro-
duct10n of a new arylsulfonyl Ui'E:d, (acetohexamide) was announced 
only recently (92). 
,~, 
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THE ARYLSULPONYLUREAS 
Carbutamide (N-butyl-H'-sulfonylurea) is a white crys-
talline solid which has the weakly ac1dic properties normally as-
sociated with the sulfonyl group. Thus it readily forms water 
soluble salts with the alkali metals, and is usually obtained as 
the sodium salt. The quantitation of free carbutamide may be 
readily performed by dlazotlzatlon and coupling reactions (19). 
The liver partially detoxifies carbutamide by acetylation and the 
resulting compound is slowly eliminated by the kidneys. As with 
the other sulfonamides containing a p-amino group, carbutamide has 
some antibacterial action and impairs the thyroid function (5,21). 
The simple replacement of the p-amino group of carbutam-
ide by a methyl group eliminates all toxic properties and gives 
rise to the hypoglycemic compound most widely used in diabetes 
therapy, tolbutamide (N-butyl-Nt-p-toluenesulfonylurea, Orinase). 
The change of the substituted group on the benzene ring is respon-
sible for many important chemical differences. Tolbutamide is a 
white crystalline solid with a melting point of 128.50 - l29.50 C., 
and is virtually insoluble in water, although it forms soluble 
salts with alkalis. It is readily soluble in the usual organic 
solvents. Various methods for the determination of tolbutamide in 
blood and urine are reported in the literature. 
In man, tolbutamide is metabolized to the carboxylic 
I ! 
I 
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acid obtained when the p-methyl group is oxidized (87); The re-
sulting compound (N-butyl-NI-p-carboxy-phenylsulfonylurea) is 
freely soluble in water and completely non-toxic. N-butyl-N'-p-
hydroxymethyl-phenyl sulfonyl urea has also been found in blood in 
very small amounts (114). This compound is probably an intermedi-
ate in the oxidation to the carboxylic acid. Finally, Mohnike and 
Witteohagen (100) isolated from the urine of dogs a toxic metabo-
lite of tolbutamide, p-toluenesulfonamide and another compound 
which was later shown to be p-toluenesulfonylurea (101). Figure 
II summarizes the known metabolic break down of tolbutamide. 
Tolbutamide is eliminated by the kidneys, primarily as 
the carboxylic acid (42). In contrast with carbutamide, neither 
tolbutamide nor its acid significantly affect thyroid function as 
assessed by 1131 studies (96). The abolition of the goiter-pro-
ducing properties of the arylsulfonylureas follows the removal of 
the p-amino group (91). 
Chlorpropamide (N-propyl-N'-p-chlorobenzenesulfonylurea) 
is a white crystalline compound melting at 12'7.5 - 128.50 C. It 
differs from tolbutamide in the replacement of the p-methyl group 
by a chlorine atom, and of the n-butyl radical by n-propyl. 
A single one gram dose of chlorpropamide produced a sig-
nificantly greater hypoglycemic effect in normal subjects than was 
produced by an identical amount of tolbutamide (136). The biolog-
ical half life of chlorpropamide is about 35 hours, which 1s 
2( 
FIGURE II 
THE METABOLISM OF TOLBUTAMIDE 
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approximately ten times that of tolbutamide (129). Evidence in-
dicates that this c~~pound, in contrast to tolbutamide, i& proba-
bly not metabolized to any appreciable extent before excretion 
through the kidneys. No definite chromatographic or ultraviolet 
absorption differences have been found between the pure drug and 
that in serum or urine (68 1 128). There is, however, a considera-
ble difference between various species of animals. Using the 
urine of dogs treated with chlorpropamide-S35, three different 
chromatographic spots were detected. They were identified as the 
unchanged compound, p-chlorobenzenesulfonylurea, and p-chloroben-
zenesulfonamide. The three compounds accounted for 30, 40, and 
20 per cent respectively (68). This serves to illustrate the dan-
ger involved in the indiscriminate application of animal experi-
ments to man. It is always necessary to take into account the 
possibility of interspecial differences. In rabbits, as in man, 
80 to 90 per cent of the chlorpropamide administered was found to 
be excreted unchanged (112). 
The increased hypoglycemic activity of chlorpropamide as 
compared with tolbutamide is probably due to the higher initial 
and more prolonged blood levels attained than to any inherent in-
creased potency (33,,{0). Thyroid function as assessed by plasma 
protein-bound iodine levels and the thyroid uptake of radioactive 
iodine is not impaired by chlorpropamide. 
Metahexamide (N-cyclohexyl-N'-(3-amino-4-toluenesulfo-
~ 
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nylurea) is a very effective hypoglycemic compound with a duration 
of actipn which is longer than that of chlorpropamide. It is 
about half as effective as chlorpropamide and about five times as 
effective as tolbutamide in producing sustained blood levels (rO). 
Dogs and rabbits excrGte 30 to 35 per cent of the administered 
dose of metahexamlde unchanged in the urine and 40 to 50 per cent 
as 3-amlno-4-benzenesulfonamide (112). Since it was found that 
metahexamide causes obstructive jaundice (89), the compound has 
been withdrawn from clinical studies. 
The newest of the arylsulfonylureas is acetohexamide 
(1- (p-acetylbenzenesulfonyl)-3-cyclohexylurea. Its chemical 
structure difters from that ot the other members of this group in 
the substitution of an acetyl group in the para position of the 
phenyl ring, and the incorporation of a cyclohexyl group on the 
urea portion of the molecule. (92). Acetohexamide is a white 
crystalline powder which is insoluble in water but soluble in al-
cohol or chloroform. Unlike tolbutamide, the sodium salt of 
acetohexamide is only sparingly soluble in water. In time activ-
ity, acetohexamide taIls between tolbutamide and chlorpropamide 
(92). In the human body it is metabolized by reduction of the p-
acetyl group. Both acetohexamide and its reduction products have 
been shown to possess hypoglycemic activity in man and animals. 
This activity of its metabolic product prolongs the hypoglycemic 
activity of acetohexamide and is at least partially responsible 
~' 
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for its relatively long durat10n of action (135). 
It is generally agreed that in mammals the arylsulfonyl-
ureas produce hypoglycemia only when some functioning beta cells 
are present. Houssay and Penhos (60) showed that the presence of 
some pancreatic tissue is essential for the hypoglycemic effect of 
the arylsulfonylureas in the same way that Loubatieres (86) demon-
strated that this was true for the sulfonylamidothiadiazoles. The 
arylsulfonylureas reduce the fasting blood sugar level of intact 
and partially pancreatectomized or mildly alloxandiabetic animals, 
but they do not do so after total pancreatectomy in dogs, rabbits, 
rats, or man (99,138), nor in animals made severely diabetic with 
alloxan. 
EXTRAHEPATIC DFECTB OF ARYLSULFONYLUREAS 
The mechanism by which tolbutamide and other hypoglyce-
mic arylsulfonylureas exert their effect is still disputed. All 
of these compounds are, at best, poorly effective in the absence 
of funotional pancreatic cells. Although the evidence indicates 
that their administration results in decreased pancreatiC insulin 
(lO'r) and increased insulin-like activity in the pancreatiC vein 
(106,109), many metabolic effects which accompany arylsulfonylurea 
induced hypoglycemia are so different from those which accompany 
insulin induced hypoglycemia that some investigators postulate the 
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presence of major extrahepatic factors of arylsulfonylurea action. 
Tolbutamide and chlorpropamide added 1!l vitro, using rat 
liver slices, have been found to decrease epinephrine-induced gly-
cogenolysis (148) and ketogenesis (1'7). When rat liver homogen-
ates were used) tolbutamide was found to alter a number of enzy-
matic activities" including at least one transaminase (16)~ sever-
al MAD and NADP requiring systems (128), and the phosphorylase re-
activating system (12). Tolbutamide and chlorpropamide adminis-
tered in vivo decreased ketogenesis (18 .. 20). Tolbutamide adminis-
--
tered in vivo, with the effect measured either in vivo or in vitro 
--.-.~ ~ -
has been found to: (a) decrease glucose output (119), (b) increase 
the syntheSiS of glycogen, fatty acids" and protein, without the 
corresponding extl':"ahepatic effects seen with insulin (111)., (c) 
decrease the conversion of fructose and galactose to glucose (6 , 
110), and (d) alter the levels of numerous enzymatic activities, 
including increased activity of malic enzyme (132). 
Chlorpropamide may slightly increase the glycogen con-
tent of rat diaphragm, while under similar conditions tolbutamide 
has no effect (31). Chlorpropamide also moderately depresses glu-
tamic-oxalacetic transaminase activity in the livers of well fed 
animals (118). These scattered reports are compatible with the 
~ypothasis that the arylsulfonylureas affect enzyme reactions 
Which depend upon pyridine nucleotides as co-factors. 
\1 
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THE GUANIDINE DERIVATIVES 
In 1926, Frank, Nothman, and Wagner (45) synthesized 
Synthalin A after earlier reports stated that the administration 
of guanidine lowers the blood sugar concentration (134). After 
very limited clinical trials, this compound was demonstrated to 
produce histological changes in the liver and kidney, and all 
further use was discontinued (13). 
In 1957, the hypoglycemic effect of phenethylbiguanide 
(N'-betaphenethylformamidinyliminourea hydrochloride) was de-
scribed by Shapiro, Parrino and Freedman (121). After investiga-
ting nearly two hundred different derivatives of formam1d1nylimi-
noureas, they found that phenethylbiguanide was a highly active 
oral hypoglycemic agent in both normal and alloxan-diabetic ani-
mala. 
The mode of action of phenethylbigl1anide differs marked-
ly from that of the arylsulfonylureas as evidenced by the facts 
that this compound is an effective hypoglycemic agent in pancrea-
tectomized animals (103L in severe alloxan-diabetes (146L and 
in patients with Juvenile or insulin deficient types of diabetes 
(108). EVidently, phenethylbiguanide does not require that func-
tional pancreatic tissue be present; this excludes the possibilit 
that it acts by stimulating the beta cells to produce more insuli 
as has been proposed for tolbutamide. Phenethylbiguanide 1n-
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creases the glu~ose upta.ke by the rat diaphragm ill vitro, while 
the muscle glycogen content decreases (141). A marked 1ncrease 
1n lactic ac1d production and a decrease in oxygen consumption 
su~est that phenethylbiguanide stimulates anaerobic glycolysis 
by inhibiting oxidative enzyme systems. 
Wick, Larson and Serif (139), using adipose tissue, 
have shown. that phenethylb1guanide inhibits the oxidat10n of glu-
cose, acetate and succinate and cons1derably reduces fat synthe-
sis. In man .. the blood pyz'uvate and lactate levels are ra1sed 
(39) and there is no ohange in hepatic vein glucose, urea, pyru-
vate or lactate, nor in the oxysen consumption of the 11ver (130). 
Lactate levels in the blood from the femoral artery also remain 
unchanged. Hypoglycemia cannot be produced in normal humans by 
the administration of phenethylbiguanide (39), although with in-
tact animals a decrease in the blood sugar concentration is easi-
ly produced. These results suggest that the effects of phenethyl 
biguanide are largely mediated in the peripheral tissues. 
The tissue anoxia suggested by this evidence may be 
attributed to inhibit10n of cytochrome oxidase and succ1nic dehy. 
drogenase (126, 131), but a decrease in oxidative phosphorylat1on 
would have the same result. Later work suggests that 'biguan1des 
inhibit the transfer of energy rich phosphate 'bonds to adenOSine 
diphosphate ({6). 
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Pileaet.r:.y1 bl6 Ilan.i..d.e has also boon fou.ad to significantly 
increase the levels of serum inorganic :vhosphate (122) whereas the 
arylaulfonylureas decrease the serum inorganic phosphate (351491 
64,129). Williams ~~. (141) found. that phenethylbiguan1de in-
hiiJi ted ~hos'phorylase phosphatase I the enzyme oa taly'zing the con-
version of phosphorylase a to phosphorylase b. They alao found 
that the compoi.lnd ha.s no effect on the activity of phosphorylase 
a 01' phos~horyla.ae b or on the conversion of phosphorylase b to 
phosphorylase a. An lr4~lbltlon of phosphorylase phosphatase ~ 
vitro would. tavor an increase in the amount ot phosphorylase a 
present in the tissue. Since pnosphorylase a 1& believed to be 
the form of the enzyme active in sl;ycogenol¥sis, this could. accoun1 
fOI' part of the decrease in glycogen produced by pheneth;ylbigua-
nide. 
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CRAnER III 
MATERIALS AND JlB'fHODS 
GENERAL EXPERIJlEftAL PROCEDURE 
'emale Sprague-Dawley rats, fed ad libitum, on a stand-
ard stock diet, were sacrificed by decapitation. The livers were 
removed without delay, washed in ice cold butter, blotted, welgh-
ed, and homogenized in cold phosphate buffer. The homogenate was 
centrifuged at lOOg to remove cella, cellular debris, and nuclel. 
A quantity of the homogenate waa then lncubated at 370 C tor two 
hours together wlth a number of cofactors, an oral hypoglycemic 
aaent, and leucine-l-C14• 
In the earlier experiments it was desired to study the 
distribution ot the label among varlous proteln fractions. Ac-
cordingly, the reaction was stopped by the addltion ot 5~ casein 
hydrolysate, which so diluted the isotope that further incorpora-
tion was negllgible. In some experlments, the diluted incubation 
mixture was subjected to sonication to releaae additional protein 
into the medium which might be held by the microsomes. After 
sonication, the mixture was centrifuged at 30,000& in a Spinco 
Ultracentrifuge (Beckman Instruments Inc., Spinco Division, 
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Belmont, California) to sediment the particulate protein (con-
sist1ng almost exclusively of mitochondr1a and microsomes). An 
aliquot ot the supernatant was precipitated tor total protein by 
the addition of 5_ trichloroacetic acidj the remainder of the su-
pernatant was utilized in an attempt to isolate beta-lipoprotein 
fraction. The traction which was sedimented in the last centri-
fugation was resuspended in buffer and an aliquot of this was 
precipitated by the addition of TeA. All precipitates were then 
assayed for radioactivity usins a thin window Geiger-Mueller 
counter. 
Later experiments were concerned with the effects of 
the concentration of the oral hypoglycemic agent on the protein 
syntheSiS, rather than the distribution of the radioactivity. 
Here, the incubations were carried out in center well flasks con-
taining potaSSium hydroxide to trap any carbon dioXide liberated 
in the course ot the reaction. The incubat10ns were stopped by 
the addition of lO~ TeA and the total protein removed from the 
flask, washed consecut1vely with 5_ TCA, ethanol, and acetone. 
Th1s was then dissolved in O.lX MaOH, an aliquot analysed for pro~ 
tein content by the b1uret reaction, and an aliquot taken to dry-
ness under a heat lamp to be assayed for radioactiVity. 
The KOH was quantitatively flushed from the center well 
of the flask into a test tube containing lO~ barium chloride. 
The resultant preCipitate was filtered, washed, and assayed for 
I 
I 
jl" ? , 
! 
1 
1,1 
~ 
)Ii ,~ 
I,' 
I 
I 
I, 
37 
radioactivity. 
CHEMICALS 
Adenosine-5t-monophosphate, sodium salt, Sigma grade. Sigma 
Chemical Co., St. Louis Mo. lot I 1138-7160 
Adenosine-S'·triphosphate, disodium salt, Sigma grade. Sigma 
Chemical Co., St. Louis, Ro. lot I l4B-7090 
Barium Chloride, General Chemical Co., Hew York, N.Y. lot # 14 
Casein h1drolysate, acid. NUtritional Biochemicals Corp., 
Cleveland Ohio lot # 8809 
Chlorpropamide, sodlum salt. Charlea Pfizer and Co. Inc., 
Bew York, N.Y. lot I 03-422-02£P» 
Cltric aCid, A.C.S. grade. Alled Chemical and ~e Corp. New York, 
N.Y. lot I 6156 
Cuprlc sulfate pentah1drate, A.R. Malllnkrodt Chemical Works 
New York, N.Y. lot I 4844 
EthJlenedlnitrl10 tetraacetic acld dlsodium salt. The Matheson 
Co., Inc., Norwood, Ohio lot I 302512 
Glucose, C.P. Malllnkrodt Chemlcal WorkS, New York, N.Y. 
lot I 4908 
Magneslum chlorlde, Baker Anal1zed Reagent. J.T. Baker Chemical 
Co., Phillipsburg, •• J. lot I 7117 
Nicotinamide, Slgma Che.ieal Co., St. Lou 1 a , Mo. lot I 1238-1810 
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Nicotinamide adenlne dinucleotide.. beta" prepared from yeast, 
Grade III. Sigma Chemical Co ... St. Louls .. MO. lot I 54B-
7090 
Phenethylblguanlde .. hydrochloride. U.S. Vitamin Corp ... New York .. 
If.Y. lot {I 21 
Phosphotungstic ac1d .. Reagent grade .. Merck & Co. Inc ... 
Rahway .. N.J. lot 1/ 41118 
potasslum blcarbonate -A.R. Mal11nkrodt Chem1cal Works, 
Ifew York .. N.Y. lot I 6748 
Potasslum Chlorlde -A.R.- Mal11nkrodt Chemlcal Works, Hew York, 
If.Y. lot II 6858 
Potassium hydroxide-U.S.P.- Allled Chemical and Dye Corp., 
New York, N.Y. lot 1/ Qo24J. 
Potass1um phosphate d1baa1c -A.R.- Malllnkrodt Chemical Work., 
New York, N.Y. lot {I 7092 
Potasaium phosphate monobas1c -A.R.- Mal11nkrodt Chemical Works, 
New York, N.Y. lot" 1100 
Potassium Sodium Tartrate tetrahydrate -A.R. Mallin.krodt Chemical 
Works, New York, H.Y. lot # 2367 
Sodium Chloride -A.R. Mallinkrodt Chemical Work., 
New York" N.Y. lot {I 7581 
Sodium hydroxide -A.R. Mallinkrodt Chemical Work., 
Hew York, N.Y. lot 1/ 7708 
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Trichloroacet1c ac1d -A.R.- Ma1l1nkrodt Chem1cal Works, 
New York, N.Y. lot I 2928 
To1butam1de - sod1um salt, The UpJohn Company, Kalamazoo, Mlch. 
lot I CJO 11,584-2 
Leucine - 1 - 014 and Leucine C14 (U.L.) 
Two isotopes were used in the experiments under cons1d-
eration. Both were obtained from the Hew England Nuclear Corp., 
Boston, Mass. and were supplied as the hydrochloride dissolved in 
O.OlR. HC1. S1nce thls excess acid might adversely aftect the 
butter systems in the 1ncubations, they were evaporated to dryness 
1n the original vials under a stream of nitrogen gas. The dry 
amino acld (present as the hydrochloride) was then dissolved in 
sufficient doubly-disti11ed water to give a final activity of 1 
uc / 50 ul ot solution. The aqueous solutions were stored in the 
freezer at - SoC and thawed immediately before use. 
The L - leucine- 1- C14 is especially valuable tor stud. 
ies in CO2 evolution, since it is labeled 801ely in the carboxyl 
carbon. Its lot number is 1'73-72-18& and it bas a specific activ-
ity ot 25.2 mllllcurles/mlllimole. The radl0 chemlcal purity of 
the materla1 was ascertalned by the manufacturer to be greater 
than 99~ as determlned by its radlochromatogram fo1loWlng descend-
ing chromatography in a solvent system conSisting ot l-butanol: 
water: acetic acld (5:4:1 v/v/v). 
t 
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The L-leucine- C14 (U.L.) was especially selected for 
incorporation studies into protein since it 1s ava1lable 1n a much 
higher spec1fic activity than that labeled solely in the 1 posi-
tion. Its lot number is 162-246-53 and 1ts specific act1v1ty is 
quoted at 223 mil11cur1es/mil11mole. Again the rad1ochromatogram 
as determ1ned by the manufacturer, 1ndicates a pur1ty 1n excess 
of 99~. 
COMPOSITION OF SOLUTIONS 
~uret reagent - 1.50g. of cupric sulfate pent&hldrate 
and 6.0 g. of potasaium sodium tartrate were dissolved in about 
500 ml. of distilled water, 300 ml. ot 10_ 5aOK waa added, and 
the resulting solution was diluted to 1000 ml. The solution was 
stored in an opaque polyethylene bottle. 
Butter solution- 11.574 g. ot ~HP04 and 1.815 g. of 
KH2P04 were dissolved 1n doubly, glass distilled water and the 
resultant solution was made up to one liter. The final molarity 
ot the solution was .08 M with respect to phosphate. The pH, aa 
measured by a Beckman pH meter, waa 7.4. 
Premix solution - The composition of the premix, essen-
tially that used by Marsh (93) tor h1s work on 1ncorporation of 
leucine 1nto l1poprotein, is given 1n Table IV. Generally in the 
execut10n ot an experiment, equal quantities of homogenate and 
I 
j 
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TABLE IV 
COMPOSITION OF PREMIX 
SUBS'rAICI MOLARITY COHee gJsO ml. 
KCl 0.075 0.280 
MgC12 ·6H2O 0.01 0.102 
00°3 0.015 0 .. 076 
Glucose 0.015 0.135 
Nicot1namide 0.02 0.122 
ID'l'A 0.0003 0.005 
lfAD 0.0025 0.092 
AMP 0.0020 0.045 
ATP 0.0020 0.062 
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premix were incubated. In the few experiments where the basic 
premix differed from this table, it will be noted in the text. 
Sodium phosphotungstate -(4~, pH 7.50- 7.60). 4.0 g. of 
phosphotungstic acid was dissolved in about 15 ml. of lX NaOH and 
th1s was diluted to 100 ml. w1th d1.stilled water, the pH being 
adjusted by addition of more base until a tinal pH or 7.50 to 
7.60 was reached. 
PREPARATION OF LIVER HOMOaENATES 
i 
I 
Livers were obtained from rats weigh1ng 200-250 grams I 
which were sacrif1ced by deoapitat1on. The 11vers were removed III 
as soon atter death as pOSSible, usually within 30-60 seconds. I 
They were then r1nsed in 1ce cold butter solution, blotted, 
weighed and ground gently in a Potter-BlvehJem homogenizer at 700 
r.p.m. for 10 complete vert1cal strokes w1th 3.0 volumes of phos-
phate butter. (O.lM, pH 7.4). The liver mash was kept at OOC 
during the entire homogenizat10n process. Unbroken cells, tissue 
debris and nucle1 were removed by centr1fugat10n at '700g. for 15 
min. at OOC. in a refrigerated centrifuge. (Internat10nal Porta-
ble Refrigerated Centrifuge Nodel PR-2 Ser1al no. 24608X). The 
homogenate was pipetted into the incubation flasks immediately 
atter centrifugation. 
ISOLATION OF BETA LIPOPROTEINS 
I. Heparin Precipitation 
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In the earller work, an adaptation of the heparin pre-
cipitation of Burstein (23) was used. After sonication of the 
incubation mixture, a quantity of rat seru~ (4-5 ml.) was added 
to supply carrier lipoprotein. This was then centrifuged for one 
hour at 100,000g in the Spinco Ultracentrifuge to remove mito-
chondria and microsomas and the clear supernatant decanted. To 
this was added a weight of sucrose equal to the volume ot the su-
pernatant. (eg. 15 g. of sucrose would be added to 15 ml of su-
pernatant so the final solution would be 100 g. ~ in sucrose). 
To the sucrose solution was added 1.1 ml. of 2M NgC12 and 1.1 ml. 
of a 1% solution of heparin in water. This was allowed to stand 
at room temperature for 20 min. and then centrifuged for 1 hour 
at 4000 g. The lipoprotein - heparin complex was found floating 
on the top of the sucrose after the centrifugation. 
The lipoprotein was isolated by filtering the solution 
under suction in a stainless-steel precipitation apparatus 
(Tracerlab model X-SB, Tracerlab Inc., Boston, Mass.) fitted with 
a disc of Whatman # 50 filter paper. The precipitate was then 
washed with O.lM MgCl to remove excess sucrose and soluble pro-
tein. (The magnesium chloride wash was used because the lipopro-
tein-heparin complex appeared to be stable in that solution 
whereas it dissociated appreciably in pure water). At this pOint, 
the precipitate was washed thoroughly with trichloroacetic acid 
solution which served to remove excess MgC12 and to denature the 
protein so that it would be retained by the filter paper through 
subsequent washing. The denatured protein was then washed with 
distilled water to remove excess trichloroacetic acid. 
Extraction of the lipid from the precipitate was a-
chieved by consecutive washings with ethanol. acetone, and ether. 
The process could be followed visually by a color change trom 
yellow to white probably due to the removal ot carotenoid pigments 
from the lipoprotein. 
The precipitate on the filter disc (consisting solely 
of the denatured protein moiety ot the beta-lipoprotein) was oven 
dried, weIghed, and counted with a thin window type assembly con-
sisting of a Tracermatic 8C-83 scaler, Tracerlab SO-100 Multi-
matic Sample Changer and Tracerlab 80-66 Printing Timer. 
(Tracerlab Inc., Boston, Mass.) 
Although the heparin precipitation was a useable tech-
nique, it suffered the severe limitation of the necessity of fil-
tering a concentrated sucrose solution. Because of this difficul. 
t¥, another isolation technique based on the phosphotungstate 
precipitation of Burstein (22) was developed and employed in the 
later experiments. 
II. Phosphotungstate Precipitation 
The procedure a.s presented 1s for a total volume of 14 
ml; the volume present after an .1ncl.4bation was .topped oy tile ad-
di tion of 5 mI. of 5% casein hydrolysate and 5 rill of carrier serum 
added. Any change in the volw~e of solution treated will neoessi-
tate a corresponding change in the ql.\B.utity of' reagents added. 
To the sonicated, centrif'uged., incubation mixture was 
added 0.75 mI. of 4% sodium phosphotungstate and O.IS mI. of 2M 
magnesium chloride. The solution was mixed by inversion and cen-
trlfuged immediately at Booo g for 20 minutes. The lipoprotein 
appeared as a yellow-orange precipitate in the bottom of the cen-
trifuge tube. 
The precipitate was washed with O.lM MgC12 in 1% saline 
and recentrifuged. It was then dissolved in 5 mI. of 0.2% sodium 
citrate and reprecipitated by the addition of 0.05 g NaCl and 0.15 
mI. of 2M NgC12 • This process of dissolution and reprecipitation 
was carried out three times to purify the beta-lipoprotein. 
The tinal precipitate was waShed twioe with 5% TeA to 
denature the protein followed by three washes with ethanol., three 
with acetone, one with benzene, and two with ether to extract the 
lipid from the lipoprotein. The white denatured protein was then 
filtered as before onto weighed Whatman # 50 filter paper and 
counted. 
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To assess the efficacy of the washes 1n removing radio-
activity not actually incorporated into protein, a 1.0 mI. aliquot 
of each wash was taken to dryness and counted on the system pre-
viously described. The data obtained from this procedure is 
given 1n the appendix. 
This procedure has the decided advantage over the hepa-
rin precipitation in that at each step one is dealing with a pre-
cipitate rather than a flocculate. (The heparin-lipoprotein com-
plex floats in the sucrose solution). It is then possible to 
merely centrifuge and decant each wash. 
CARDIAC PUNCTURE 
'!he serum which was to serve as a source of carrier 
lipoprotein was obtained by perfol~ing cardiac puncture on 200-
300 g. rats. The blood thus obtained was allowed to clot, cen-
trifuged to separate the red blood cells from the serum, and 
stored in the cold until used. In obtaining the blood samples 
the rat was anaesthetized with ether' until it ceased struggling. 
A 3/4 inch, 25 gauge needle attached to a flve c.c. syringe was 
introduced immediately distal to the sternum and pushed forward 
through the ohest cavity. The needle was introduced completely 
into the rat and then with the syringe plunger slightly extended, 
was slowly withdrawn from the rat. When the point of the needle 
4{ 
was within the heart, the syringe began to fill with blood. The 
syringe was maintained in that posit1on until a 1-2 ml. sample of 
blood had been obtained. 
PROTEIN ISOLATION 
In the ear11er work, an aliquot of the homogenate (usu-
ally 1.0 ml.) was pipetted lnto a glass stoppered centrlfuge tube, 
4.0 ml. of 5. TeA were added and the resultant preCipitate centri-
fuged down. It was then washed consecutively with 5~ TCA, 95_ 
ethanol, acetone benzene and ether. After the final ether wash, 
the white precipitate waa re-suspended in 5.0 ml. of ether and 
filtered through a weighed disc ot Whatman # 50 fl1ter paper using 
the stainles8-ateel precipitat10n apparatus vrevioualy mentioned. 
The amount of protein present was determined simply as dry weight 
of proteln - TeA precip1tate. There were two principal disadvan-
tages to this procedure; the determination of protein on a dry 
weight baSis was not sufficiently accurate and the geometry of the 
final plated smaple waa very poor. The preCipitate had a strong 
tendency to crack; this would result in a significant variation in 
results when the sample was counted. 
Accordingly, a different procedure was utilized 1n later 
experiments when the reaction waa stopped by the addition of TeA. 
The preCipitated protein was transferred quantitatively from the 
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incubation flask to a glass stoppered centrifuge tube. It was 
centrifuged and the precipitate washed with 5~ TCA. The precipi-
tate was then washed three times with 95% ethanol and three times 
with acetone. The efficiency of the washes in removing non-incor-
porated leucine- C14 was determined by plating out a 1.0 ml. ali-
quot of each wash, evaporating 1.t to dryness and counting the 
dried sample w1th a thin window Geiger-Mueller counter. The data 
in Table XXIII 1n the appendix clearly indicates that the above 
procedure provides adequate purification. 
After the final acetone waSh, excess acetone was removed 
by gentle suction with an aspirator and the prlclpltate dissolved 
in 2.0 ml. of O. IN sodium hydroxide. A 1.0 ml. aliquot of this 
solution was taken to dryness in a planchet and counted to deter-
mine the incorporation into protein. No correction was made for 
self-absorption due to HaOH, slnce this was constant for each sam-
ple. The geometry of samples so plated was excellent; each 
planchet conta1ned a uniform thin layer of so11d material on the 
bottom. The amount of protein in each centrifuge tube was deter-
m1ned by means of a biuret reaction, run in duplicate, on the 
remainder of the solution. 
PROTEIN DETERMINATION 
During some of the earlier experiments, protein was 
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merely assayed as dry weight of TeA precipitate. Later, this was 
felt to be too crude for more exact work~ and a modificat10n of 
the biuret determination of Gornall, Baradawill and David was em-
ployed (51). One mI. or less of the sample to be measured was 
placed in a colorimeter tube. To this was added 4.0 ml of biuret 
reagent and sufficient distilled water to make a total volume of 
5.0 mI. and the solution was allowed to stand for twenty minutes 
before being read 1n a Klett- Summerson vhotoelectric colorimeter 
fitted with a # 54 filter. Blank tubes contained 4.0 ml of biuret 
reagent, 0.2 mI. of O.lN sod1um hydroxide and 0.8 mI. of water. 
Samples tubes contained 0.2 mI. of sample~ (TeA ~rotein precip1-
,I 
I' 
tate dissolved in NaOK as described previously)" 0.8 mI. 01' water II 
and 4.0 mI. of biuret reagent. Standardization tubes contalned 
1.0 mI. of a solution containing 1.0 to 10.0 mg. of bovine serum 
albumin and 4.0 mI. of bIuret reagent. Protein concentration was 
expressed in terms of mg. pro1a..n nItrogen. 
All colorimeter tubes were calIbrated against each other 
before use and a blank and a standard were run with each deter-
mination. All sample determinations were run in duplicatej the 
determinations for the standard curve were run in triplicate. 
The data for the calibration curve i8 given in Table V 
and the standard curve appears in rigure III. 
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TABLE V 
STAJlDARD CURVE DATA 1'OR PROTEIN DETERMINATION 
Klett Units 
16.0 
14.0 
15.0 
28.5 
31.0 
30.5 
45.5 
44.0 
44.5 
60.0 
64.0 
61.0 
77.0 
78., 
76.0 
92.0 
92.5 
91.0 
123.0 
119.0 
121.5 
152.0 
150.0 
154.0 
Average 
15.0 
30.0 
44.7 
61.7 
Tl.2 
91.8 
121.2 
152.0 
Standard 
Deviation 
1.0 
1.3 
0.8 
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C1402 Collection and Measurement 
Incubations in which the amount of C1402 evolved was to 
be determined were carried out in stoppered center well Erlenmeye 
flasks (25 ml. capacity). The center well contained a piece of 
filter paper saturated with 0.2 ml. of 10. KOB to trap the CO2; 
the main body of the flask held the incubation mixture. After 
the incubation was stopped; each flask was allowed to shake for 
30 minutes longer to allow all CO2 present to come into contact 
with the KOB. 
After the precipitated protein was removed from the 
flask, the filter paper was extracted from the center well with a 
palr of forceps and placed ln a test tube containing 2 ml. of 
water. After shaking, the water was decanted into another tube 
containing 5.0 ml. of lO~ barium chlorlde. The filter paper was 
washed a total of three tlmes ln this manner. The center well 
itself was washed a total of five times with dlstilled water and 
these washing were also added to the BaC12• 
The preCipitate of BaC03 which formed was fl1tered on 
pre-welghed Whatman # 50 filter paper using a Tracerlab Precipi-
tation Apparatus, Model B8-B. The precip1tate was washed three 
times with doubly-dlst111ed water, 50-50 (v/v) ethanol-acetone 
and finally w1th pure acetone and allowed to dry for about two 
hours before weighing and counting. 
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The counting was done 'with a thin window type assembly 
consisting of a Tracermatlc SC-83 scaler" Tracerlab SG-IOO Multl-
matlc sample chal~er and Tracerlab 8C-66 Printing Timer. All 
samples were corrected tor self-absorption and dead time. Correc 
tiona for self absorption were made according to the following 
equation (145) 
where I • observed actIvity" 10 • actual activity, u • 0.29 
and h • mg/cm2 of the plated material. The self-absorption cor-
rection curve appears in Figure IV and the pertinent data is give 
in Table VI. 
An approximate correction was made for resolving time 
by adding O.5~ per 1000 cpm to the observed counting rate (28). 
The day to day performance of the instrument was checked by count-
ing the same uncalibrated C14 source with each group of samples. 
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TABLE VI 
SELF-ABSORPTION CORRECTIONS lOR BaCO~ 
I 
t 
IDg BaC03 I/Io mg BaC03 1/10 
0.0-0.4 1.00 6.7-6.8 0.72 
0.5-0.6 0.98 6.9-'7.2 0.71 
0.7 0.95 7.3-7.7 0.70 
0.8-0.9 0.94 7.8-8.0 0.69 
1.0-1.5 0.93 8.1-8.3 0.68 
1.6-1.7 0.92 8.4-8.6 0.6'7 
1.8-1.9 0.91 8.7-8.9 0.66 
2.0-2.1 0.90 9.0-9.3 0.65 
2.2-2.3 0.89 9.4-9.6 0.64 
2.4-2.6 0.88 9.7-10.0 0.63 
2. 'r-2.9 0.87 10.1-10.4 0.62 
3.0-3.1 0.86 10.5-10.8 0.61 
3.2-3.4 0.85 10.9-11.2 0.60 
3.5 0.84 11.3-11.6 0.59 
3.6-3.8 0.83 11.7-12.1 0.58 
3.9-4.1 0.82 12.2-12.4 0.57 
4.2-4.4 0.81 12.5-12.9 0.56 
4.5 0.80 13.0-13.3 0.55 
4.6-4.9 0.79 13.4-13.8 0.54 
5.0-5.2 0.78 13.9-14.1 0.53 
5.3-5.4 0.77 15.0 0.51 
5.5-5.'7 0.76 15.5-15.8 0.50 
5.8-6.0 0.75 16.0 0.49 
6.1 ... 6.3 0.74 17.0 O.4{ 
6.4-6.6 0.73 20.0 0.43 
CHAPTER IV 
EXPERIMENTAL RESULTS 
Ex12er1ment 1: Change.!!l ~ During !h!. Course .2!. !h!. Incubation. 
Before any actual incubations were performed, it was de-
cided to determine the pH of the different solutions in order to 
ascertain whether ditterences which misht be obtained would be due 
to the presence of the hyposlycemic agentl rather than to an ini-
tial ditference in pH. AccordinglYI the pH ot the buffer alone l 
the premix alone and the homogenate alone were determined by means 
ot a Beckman pH meter. 
A simulated incubation was then run containing premix 
(1.0 mI.) homogenate (1.0 ml ot 2:1 v/w rat liver homogenate), an 
hypoglycemic agent (4 x 10 -3 M). Only the isotope was omitted 
from this incubation. Flasks were gently agitated at 3'{oC for 2 
hours and the initial and tinal pH at each sample recorded. The 
data are presented in Table VII. 
It was felt that the final pH represented too low a val-
ue, so the incubation was repeated using a 311 vlw homogenate. 
Again the initial and final pH was measured and the results tabu-
lated. Since the pH change in this case was considerably smallerl 
TABLE VII 
THE pH OF THE INCUBATION MIXTURES 
I. pH of Constituents of Mixtures 
pH buffer 
pH premix 
pH homogenate (2:l) 
pH homogenate (3:1) 
1.42 
7.33 
"{.04 
'{ .23 
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II. pH of Incubation MLxtures Using 2:1 Homogenates 
Addition 
Tolbutamide 
Chlorpropamide 
Phenethllbiguanide 
2H start 
'7.04 
7.02 
7.02 
pH finish 
6.86 
6.82 
6.59 
III. pH of Incubation Mixtures Using 3:1 Homogenates 
Addition 
Tolbutamide 
Chlorpropamide 
Phenethllbiguanide 
pH start 
7.23 
7.21 
7.23 
pH finish 
7.02 
1.01 
6.80 
IV. pH of Homogenates Prepared at Different Times-Constancy 
of pH 
Date 
8/11/64 
ff/13"/64 
8/14/64 
a-/19"/64 
9/i4/64 
10/15/64 
11/ 4/64 
Type 
rat liver 
rat liver 
rat liver 
dog liver 
rat liver 
rat (2) liver 
rat liver 
E! 
1.23 (.08 
'{ .18 
7.18 
7.18 
r{.22 
'7.22 
I III 
! 
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it was decided that the 3:1 homogenate would be used in all suc-
ceeding experiments. 
The observation (Table VII) that there is a greater pH 
drop in the flask containing phenethylbiguanide than in the flasks 
containlng the sulfonylureas is compatible with the observations 
of Dalidowicz (34). Th1s must imply that phenethylblguan1de un-
dergoes some reactlon, peculiar to that agent alone, which re-
leases hydrogen ion into the medium. This represents just one 
more indication that the mode of actlon of phenethylbiguanide is 
entirely un11ke that of the arylsulfonylureas. 
Experiment 2: ~ Incorporation 2! Leucine- C14 ~ Beta-Lipo-
protein: Effect ~ Differing Isotope. 
Incubations were run in duplicate at 370 e. for a ~eriod 
of two hours. One incubation flask was kept at oOe. to serve as a 
control. Radioactivity present in the lipoprotein above that 
present in the oOe flask was interpreted as representing incorpo-
ration. The inoubations were run using 2 uc of either leucine-l-
e14 (U.L.), the latter possessing a much higher specific actiVity. 
Lipoprotein was separated by the heparin technique of Burstein 
(23). 
The results in Table VIII indicate that a very small a-
mount of incorporation occurred using the isotope of lower specif-
ic activity. A more significant amount of lncoI~oratlon was 
~ 
I 
j 
I 
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TABLE VIII 
INCORPORATION OF LEUCINE INTO BETA-LIPOPROTEIN: 
EFFECT OP SPECIFIC ACTIVITY OF ISOTOPE. 
Incub. Leuclne-1-C14 Leucine-C14 (U.L.~ 
temp (sp. act. 25mc/mm) (sp. act. 233mc/mm 
3'(oC 36 cpm 112 cpm 
3'7°C 32 cpm 69 cpm 
37°C 30 cpm 84 cpm 
oOe 21 cpm 21 cpm 
oOe 22 cpm 25 cpm 
background 20 cpm 18 cpm 
! 
!, 
I 
I 
I'i 
)'" q 
~! ,~ 
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evident when the leucine with the higher spec1f1c activity was 
used, but the results were not very reproducible. 
Experiment J: ~ Incorporation ~ Leucine - C14 into Beta-Lipo-
protein. Effect!! Tolbutamide Addition ~~ Omission 2t Premi~ 
Each incubation flask contained 2 uc of leucine - C14 
(U.L.) in a total volume of 2.0 mI. Tolbutamide was added to two 
flasks as the sodium salt, to give a final concentration ot 
4 x 10 -3 M. In two other flasks the 1.0 ml of premix was re-
plaoed by an identioal amount of distilled water. The inoubation 
was conduoted for two hours, at 370 C and the contents sonicated 
tor 30 min. before the lipoprotein was isolated by heparin pre-
cipitation. 
The data (Table IX) are not sufficiently aocurate to de-
term1ne the effect of tolbutamide on the beta-lipoprotein synthe-
Sis. There may be a slight inhibition, but this is uncertain. 
However, it is apparent that the omiSSion of the premix results in 
a lowered inoorporation of isotope into the lipoprotein. This ob-
servation substantiates the work of Marsh (93) who first demon-
strated incorporation into lipoprotein. Since Marsh separated 
lipoprotein ultracentritugally, this substantiation of his results 
by heparin precipitation would ind1cate that there is genuine syn-
thesis taking place; the radioactivity associated with the lipo-
protein is not merely an artIfact of the method. However, 
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TABLE IX 
INCORPORATION OF LBUCIHB INTO BETA-LIPOPROTEIN: 
DRCT OF TOLBUTAMIDE ADDITION AND or OMISSION 01' PREMIX 
Experimental 
Procedure 
370 incubation 
370 incubation 
Tolbutamide added 
Tolbutamide added 
Premix omitted 
Premix omitted 
00 control 
Background 
cpm 
80 
50 
58 
35 
30 
29 
19 
20 
Ilil 
II. 
:1 
~ 
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although the isotope 1s definitely incorporated into the lipopro-
tein, the resultant activity ia not sufficient to yield reproduc-
ible data. 
Experiment 4: D1stribution ~ Radioaetivity ~ Various Protein 
FractIons. 
Since there was apparently very little label being in-
corporated into the beta-lipoprotein fraction, it was decided to 
investigate the relative amount found in various protein fraction 
Four flasks were incubatedj 2 controls, 1 containing 4 x 10 -3 M 
tolbutamide, and 1 containing 4 x 10 -3 M orotic acld. This last 
chemical was employed because it has been postulated to inhibit 
hepatic lipoprotein secretion (144). 
Each incubation flask contained 2.0 ml of premix, 2.0 
ml. of homogenate and 10 ucuries of leucine-Cl4 (U.L.). After 2 
hrs. incubation at 31°C, each flask was stopped by the addition 
of 5.0 ml. of 5% casein hydrolysate. After sonication, the con-
tents were centrifuged for 1 hour at 100,OOOg. to sediment mito-
chondria and microsomes. These particles represent one fraetion 
which was studied. They were resuspended in 4.0 ml. of buffer by 
gentle homogenization and a 1.0 ml. aliquot of the suspension was 
precipitated with TeA, washed, evaporated to dryness and counted. 
A 1.0 ml. aliquot of the supernatant liquid (which was 
': 
i' 
i 
" 
I 
I' ~ 
i 
separated from the sedimented particles by decantation) was 
cipitated for protein by the addition of 4.0 ml. of 5% TCA, 
washed and counted. 
63 
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Carrier plasma was added to the remainder of the super-
natant and the beta-lipoproteins were isolated by phosphotungstate 
precipitation, washed and counted. Thus the original incubation 
mixture was separated into 3 components: The particulate proteins, ,:!III 
!:'~J 
the total soluble proteins and the beta-lipoproteins. This sepa-
ration is illustrated schematically in Figure V. 
It is apparent from the data in Table X that there is a 
very significant degree of incorporation of leucine in both the 
soluble protein and the particulate protein. Furthermore, tolbu-
tamide inhibits the incorporation into both fractions to approxi-
mately the same extent. The presence of orotic acid has no ef-
fect on incorporation into either fraction. The data concerning 
lipoprotein incorporation is less certain; the amount of activity 
present is still not large. No attempt was made to calculate the 
specific activity of the lipoprotein, since the amount isolated 
was too small to measure accurately. It appears that both tolbu-
tamide and orotic acid inhibit lipoprotein synthesis, but the 
proof is far from conclusive. 
I 
I 
! I 
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FIGURE V 
SEPARATION OF PROTEIN FRACTIONS 
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TABLE X 
DISTRIBUTION OF RADIOACTIVITY 
Fraction 
Protein-soluble 
no addition 
no addition 
tolbutamide 
orotic ac1d 
Protein-particulate 
no addit10n 
no addition 
tolbutamide 
orot1c acid 
Beta-11poprote1n 
no addition 
no addition 
tolbutam1de 
orotic acid 
Weight 
mg. 
4.8 
4.6 
4.0 
4.8 
9.0 
8.7 
10.1 
9.1 
Counts 
3000 
3000 
3000 
3000 
3000 
3000 
3000 
3000 
3000 
3000 
3000 
3000 
Time 
(min) 
~r .22 
6.62 
11.64 
7.14 
0.'79 
0.99 
1.41 
0.96 
31.12 
34.13 
54.81 
85.47 
cpm 
416 
453 
258 
420 
3197 
3030 
2128 
3125 
96 
88 
55 
35 
cpm/mg 
8'7 
98 
65 
88 
422 
348 
211 
343 
1 
a 
~! I 
!.' f 
f 
:iil 
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Experiment 5: ! Comparison 2t~ Effect 2t Tolbutamide ~ 
Phenethylbiguanide ~!h! Incorporation ~ Leucine ~ Various 
Protein Practions. 
The incubations and subsequent separations were carried 
out precisely as 1n the preceding experiment. Data for this ex-
periment are presented in Table XI. These results confirm the 
previous observations that tolbutamide inhibits incorporation of 
the isotope into both the soluble and the particulate protein. 
In contrast to this, phenethylbiguanide does not appear to have 
an inhibitory effect in either fraction. It appears that tolbuta 
mide might have an inhibitory effect in the beta-lipoprotein frac 
tion, but phenethylbiguanide probably does not. A concise summa 
of the data obtained from the last two experiments is presented 
in Table XII. 
Since a very early step in the catabolism of leucine 
(Figure VI) involves a decarboxylation reaction, it was decided 
to trap the CO2 liberated in the course of the incubations sad to 
determine the effect of tolbutamide and phenethylbiguanide on leu 
cine oatabolism as well as anabolism. For the first experiments, 
leucine - 1 01 4 was employed, so that there would be a strict one 
to-one correspondenoe between the amount of leuoine catabolized 
and the amount of Cl40 produced. 2 
'I 
~ j 
TABLE XI 
DISTRIBUTION OF RADIOACTIVITY 
INCUBATION WITH TOLBUTAMIDE AND PHENETHYLBIOUANIDE 
Fraation Weight Counts Time apm 
mg. (min) 
Protein-soluble 
no addition 11.0 3000 3.18 943 
no addition 11.0 3000 2.62 1145 
tolbutamide 9.8 3000 5.07 592 
tolbutamide 9.3 3000 5.29 56'7 
phenethylbiguanide 9.6 3000 3.27 917 
phenethylbiguanide 10.3 3000 3.03 990 
Protein-particulate 
no addition 5.3 10000 1.91 5076 
no addition 6.0 10000 1.85 5368 
tolbutamide 6.2 10000 2. '{l 3690 
tolbutamide 5.9 10000 2.57 38g1 
phenethylbiguanide 5.2 10000 1.85 5405 
phenethylbiguanide 5.8 . 10000 1.51 6369 
Beta-lipoprotein 
no addition 8.3 3000 '7.62 394 
no addition 7.8 3000 8.9'( 334 
tolbutamide 4.0 3000 18.64 161 
tolbutamide 9.9 3000 8.57 350 phenethylbiguanide '7.0 3000 8.99 334 phenethylbiguanide 11.2 3000 5.50 545 
~ 
'I:" 
~ 'l~ 
1':1 
apm/mg 
~ II , 
(I 
'I!I 
I!'I' 
"I 
"Ii iii I! 
,I 
" I 
86 
104 
60 
61 
f 96 96 
It 
!i: 
I 
, 
i 
958 'II 
964 
595 
659 
1039 
10g8 
I" 
, 
47 I 
43 
40 
35 
48 
49 "i)1 
I,ii 
~~I 
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TABLE XII 
SUMMARY 07 EXPERIMENTS 4 AND 5 
Fract10n 
Protein-soluble 
Control 
tolbutamide 
phenethylblguanide 
Protein-particulate 
Control 
tolbutamide 
phenethylbiguanlde 
Beta-lipoprotein 
control 
tolbutamide 
phenethylb1guanlde 
Experiment 4 
Average % of 
sp. act. Control 
93 100 
65 '70 
385 100 
211 55 
Experiment 5 
Average % of 
sp. act. Control 
95 100 
60 63 
96 100 
961 100 
528 '{O 
1003 105 
45 100 
38 85 
48 106 
, ' 
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FIGURE VI 
THE CATABOLISM 0' LEUCINE (137) 
H3C N~ 
, b it H3c/CH-C~1- H-C OOH 
transamination 
H3C 0 \ II 
H C 
3 
CH .. C~-C-COOH 
/ 
CoASH 
1 -2H H C 3 \ II C-CH-C-SCoA 
/ 
H3C 
HOOC-C~ ~ 
C-CH-C-SCoA 
H3C' 1 H20 
HOOC-C~ ~H 9. H3C-H-C~-COOH 
/C-C~-C-SCoA --~) 0 
H3C H3C-C-SCOA II 
o 
69 
"I ~ 
I 
i 
'I 
:,1 
:11 
.ill 
.~ I 
'70 
Experiment 6: Effect ~ Tolbutamide ~ Phenethylbiguanide ~ 
c1492 Production from Leucine - 1 _ C14 • 
For this experiment" five flasks were incubated as 
usual. Two contained 4 umoles of tolbutamide~ two contained 4 
umoles of phenethylbiguanlde, one contained no added agent. The 
CO2 liberated in the course of the incubation was trapped in KOH 
in the center-well of the incubation flask. This was isolated as 
BaC03 and counted. The incubation was stopped after two hours by 
the addition of 0.5 mI. of IO~ TCA and the resulting pI'otein pre-
cipitate was likewise isolated and counted. The data is tabulat 
in Table XIII. 
It will be noted that the C02 data are expressed as 
total cpm rather than as specific activity (cpm/mg). Since the 
reason for this is not immediately apparent, a brief discussion 
might be useful. Since the total CO2 comes from many places othe 
than Just the decarboxylation of leucine (e.g. Krebs cycle), the 
specific activity is a meaningless expression. This is sobecaus 
the effect of the oral hypoglycemic agents on these other sources 
of C02 is not known and the specific activity will necessarily 
vary as the total weight of CO2 (as BaC03) varies. Thus the spe- I 
cific activity would be different if tolbutamide were to depress 
the Kr'ebs cycle from if' it were to accelerate it. 
To clarify the ~bove, the following hypothetical case 1 
Il 
TABLE XIII 
CO2 RELEASE AND PROTEIN INCORPORATION FROM EXPERIMENT 6 
C02 DATA (CATABOLISM) 
--
Sample Weight Counts Time cpm cpm 
mg. (min) corr. 
control 7.3 300K 9.61 31,200 51,550 
tolbutamide 5.5 300K 8.41 35,700 55,400 
tolbutamide 5.7 300K 7.80 38,500 60,400 
phenethylbiguanide 4.1 300K 17.59 1'[,,000 22,500 
phenethylbiguanide 4. '{ 300K 17.00 1'7,600 24,300 
PROTEIN INCORPORATION (ANABOLISM) 
Sample Weight Counts Time cpm cpm/mg 
mg. (min) 
control 4.8 10K 1.56 1320 276 
tolbutamide 4.6 10K 18.38 543 118 
tolbutamide 5.0 10K 14.64 682 136 phenethyl b1guan ide 5.1 10K 9.97 1000 196 phenethy1biguanide 4.8 10K 9.10 1100 229 
I
III 
I' 
" 
I 
{2 
considered. Substance x depresses the oatabolism of leucine only 
and has no effect on other sources of C02- Substance y depresses 
the catabolism of leucine but also depresses CO2 production via 
the Krebs cyole. 
control 
x added 
y added 
cpm 
100 
25 
25 
CO2 trom 
leucine 
5 mg 
1.25 rag 
1.25 mg 
5 mg 
5 mg 
1.25 rag 
cpm/mg 
10 
4 
10 
In this example, substance y reduces the decarboxylation 
of leucine by a factor of 4. This eITect i8 not evident from a 
conSideration of the specific activItIes because it also reduces 
the amount of CO 2 produced from other' sources. 
From the data obtained in experIment 6, it is apparent 
that tolbutamide bas little etfect on the catabolism of leucine, 
whereas phenethylblguanide has a very 8ignificant inhIbitory ef-
fect. The previously observed effects on protein synthesis are 
verified in this experiment; phenethylblguanlde has little effect 
while tolbutamide exerts a significant inhibition. 
From the data in thi8 experiment, the ratio ot catabo-
li8m to anaboliSM can be calculated. 
catabolIsm 
anabolIsm • • 39 
73 
This I'esult indicates that for each mol(:-)cule of leucine incorpo-
rated into protein und(:-)l:' control conditions, 39 molecules are 
being broken down. The system under study is a highly catabolic 
one. 
Experiment '{: ~ Effect .2f. Three 19Poglycemic Agents .2!!. Leucine 
Anabolism and Catabolism. 
-
This experiment was designed to be a verification of 
the previous observations, with the inclusion of chlorpropamide 
effects on protein incorporation and CO2 release. The incubation 
flasks contained 0.5 mI. of homogenate; 0.5 mI. of premix, 1 uc 
of leucine-l-C14J and sufficient oral hypoglycemic agent to make 
the final concentration 4 x 10-3 M. The hypoglycemic agents were 
added in 1.0 mI. of water, making a total volume in each incuba-
tion flask of 2.0 mI. The experimental flasks incubated consisted 
of: 1 kill flask to which was added 0.5 mI. of 10~ TCA before in-
cubation, 1 control flask containing no hypoglycemic agent, and 
2 each of flasks containing 4 x 10 -3 M tolbutamide, chlorpropa-
mide and phenethylbiguanlde. Data are presented in Table XIV. 
The data on the release of C1402 verify that obtained 
in experiment 6. The presence of tolbutamide exerts little or no 
effect on the catabolism of leucine. Phenethylbiguanlde has a 
significant inhibitory influence on it and chlorpropamide has an 
~.I' , [~, 
l, 
II. 
", I  I 
" 
TABLE XIV 
EFFECT OF TaHEE AGENTS ON 
ANABOLISM AND CATABOLISM OF LEUCINE 
Sample 
no addition 
tolbutamide 
tolbutamide 
Chlorpropamide 
Ch.1.orpropam1de 
phenethy1biguan1de 
phenathylbiguan1de 
k111 (TCA) 
Sample 
no add1tion 
tolbutamide 
tolbutamide 
chlorpropamlde 
chlorpropamlde 
phenethy1blguanide 
phenethylbiguanide 
kill (TCA) 
Weight 
mg .. 
8.l. 
5.0 
'7.5 
5.9 
5.8 
7.3 
8.3 
11.3 
We1ght 
mg. 
7.1 
5.9 
5 • .5 
5.8 
5.( 
6.1 
5.7 
5.3 
C02 DATA 
---
Counts 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
2352 
PROTEIN DATA 
-
Counts 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
5224 
Time 
(m.:.n) 
8.70 
8.25 
9.36 
12.50 
12.52 
12. '{4 
12.83 
23.50 
Time 
(min) 
60.34 
4'{.56 
58. '12 
54.48 
52.97 
'73.14 
~1.o8 
290.18 
epm 
11,494 
12,121 
10,684 
8,000 
l,98T 
7,849 
'I, 794 
100 
cpm 
166 
210 
1{0 
184 
189 
137 
122 
18 
r4 
cpm 
cerro 
11','749 
16,904 
16,091 
11,093 
11.,076 
11,641 
11,902 
169 
cpm/mg 
23 
36 
31 
32 
33 
22 
21 
3 
l 
I 
II 
! 
II 
I 
!I 
i 
i! 
15 
effect very similar to phenethylbiguanide. This last observation 
i8 most surprising, since chlorpropamide is veI7 sim.1.1ar struc-
turally to tolbutamide and totally unlike phenethylbiguanlde. 
The protein data. from this experiment are inconclusive, 
since the specific aotivities obtained are too low to be meaning-
ful. This is evidently a result of the dilution of the incuba-
tion mixture (it was one-half as concentrated as in previous ex-
periments) and the faot that only 1 uc. of leucine-l-C14 was add-
ed to each flask. 
Experiment 8: ~ effect ~~ Concentration 2t Phenethl1-
biguanide on 014°2 Evolution. 
The Experimental procedure was similar to that employed 
in experiment 7, but protein incorporation was not determined. 
Incubation flasks contained 0.5 ml. premix, 0.5 ml. homogenate 
and 1 uc of leucine - 1 - C14• Added to this was a varyir~ &moun 
of phenethylbiguanlde (from 0-30 umoles) dissolved in 1.0 ml. of 
H20, so that the total volume of each flask was 2.0 ml. The radi 
activity present in the C02 collected is given in Table XV. 
The inhibition of CO produotion is illustrated graphio 
ally in Figure VII. 
jl 
I 
I 
I 
I 
Ii 
I 
;1 
i 
Umo1es of 
PlmG added 
0 
0 
4 
4 
8 
8 
12 
12 
16 
16 
20 
30 
30 
TABLE XV 
EFfECT 0' CONCENTRATION OF PBEHETHYL-
BIGUANIDE OR 01402 EVOLUTION (Experiment 8) 
Wei~ht 
BaC03(mg • ) 
9.3 
9.3 
8.2 
7.0 
16.2 
10.7 
6.6 
8.9 
10.4 
13.8 
6.6 
9.2 
'7.9 
Counts 
30K 
30K 
30K 
30K 
30K 
30K 
30K 
30K 
30K 
30K 
30K 
10K 
10K 
Time (min) 
5.52 
5.07 
6.45 
6.06 
10.76 
8.04 
8.46 
9.24 
10.22 
11.62 
9.64 
3.58 
3.51 
cpm 
5440 
5930 
4650 
4945 
2785 
3'735 
3542 
3250 
2935 
2580 
3115 
2795 
2850 
'76 
cpm 
corr. 
8590 
9400 
6960 
'7140 
5T(0 
6240 
4950 
5000 
4810 
4850 
4340 
4360 
4180 
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Experiments 2 & 10: !h! Etfeot ~~ Conoentration ~ Phenethyl-
biguanide on C140 Evolution and Protein Inoorporat1on. __2 ... ______________ _ 
Inoubations were performed us1na 0.5 mI. of homogenate, 
0.5 mI. of premix, 2 uouries of leuo1ne- 1- 014, and varying a-
mounts of phenethylbiguanide. The total volume in eaoh rlask was 
1.0 mI. Evolved CO2 was trapped in the center well and total pro 
te1n was precip1tated and counted. The protein was dissolved in 
NaOH and plated out as suoh. Its ooncentrat1on was measured by 
means of the biuret reaction. 
The data for experiment 9 appears in Tables XVI and 
XVII. Experiment 10 was designed as a verification or this exper 
iment, and the results are presented in the appendices in Tables 
XXIV and XXV. 
Experiment 11: ~ Erteot £! ~ Conoentration £! Tolbutamide ~ 
C140 Bvolution and Prote1n Inoorporation. __2;::. ____ _ 
The experiment was performed exactly as the preoeding 
two, exoept that tolbutam1de was substituted for the phenethyl-
biguan1de. Both prote1n and CO2 were oolleoted and counted as 
before. Results are given in Tables XVIII and XIX. A oomparison 
of the relative effeots of tolbutamide and phenethylbiguan1de on 
CO2 produotion and protein syntheSiS is presented 1n Figures VIII 
TABLE XVI 
EFFECT OF CONCENTRATION OP PHINETHYL-
BIGUANlDE ON C140
2 
EVOLUTION (Experiment 9) 
19 
TABLE XVII 
EFFECT OP CONCENTRATION OP PHENETHYLBIGUANIDE ON 
INCORPORATION OF LEUCINE-I-C14 INTO 
PROTEIN OP RAT LIVER. 
Umoles of 
PEBa added 
0 
0 
2 
4 
4 
6 
6 
8 
8 
10 
10 
15 
15 
Weight 
Protein mg. 
7.45 
7.65 
6.85 
6.95 
'7.15 
6.95 
6.65 
"( .00 
6.65 
6.80 
7.15 
'{ .10 
7.05 
Counts 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
Time 
(min) 
6.70 
5.59 
7.47 
8.33 
7.41 
10.33 
8.19 
18.64 
14.33 
33. '79 
49.42 
50.43 
50.11 
cpm 
1493 
1789 
1339 
1200 
1350 
968 
1221 
536 
698 
296 
202 
198 
200 
80 
cpm/mg 
200 
234 
195 
1'73 
189 
139 
184 
1'7 
105 
44 
28 
28 
28 
tTmoles of 
Tolbutamide 
added 
0 
0 
2 
2 
4 
4 
6 
6 
8 
8 
10 
10 
15 
15 
TABLE XVIII 
EFFECT or CONCENTRATION OF TOLBUTAMIDE 
ON 014°2 EVOLUTION 
weifht 
BaC03 mg.} 
12.5 
11 .. '{ 
10.8 
10.3 
13.2 
12.5 
11.3 
11.0 
14.1 
15.9 
13.9 
,{.3 
6.6 
11.7 
Counts 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
Tlme 
(min) 
3.42 
3.25 
3.52 
3.18 
3.96 
3.66 
3.97 
4.20 
4.91 
5.22 
5.25 
4.43 
4.04 
4.55 
cpm 
291 200 
30,,{00 
28,400 
31,400 
25 .. 300 
27,300 
25 .. 200 
23,800 
20,400 
19,200 
19,000 
22,600 
24,800 
22,000 
81 
cpm 
eorr. 
60,000 
61,100 
53,100 
58,500 
51 .. 800 
55,300 
48,100 
44,400 
42,300 
42,900 
39,300 
36,000 
38,200 
42,100 
Umo1es of 
tolbutamide 
a.dded 
0 
0 
2 
2 
4 
4 
6 
6 
8 
8 
10 
10 
15 
15 
TABLE XIX 
EFFECT OF CONCENTRATION OF TOLBUTAMIDE 
ON INCORPORATION OF LEUClNE-1-C14 INTO 
PROTEIN OF RAT LIVER 
Weight 
Protein mg. 
8.60 
8.45 
8.35 
8.45 
8.20 
8.00 
8.35 
7.80 
7.65 
7.95 
7.60 
7.80 
8.10 
8.70 
Counts 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
10K 
Time 
(min) 
4.85 
4.44 
5.94 
5.02 
5.62 
5.68 
6.81 
7.11 
8.41 
9.81 
8.46 
7.45 
9.14 
10.82 
cpm 
2062 
2252 
1684 
1992 
1779 
1'[60 
1468 
1406 
1189 
1019 
1182 
1342 
1094 
924 
82 
cpm/mg 
238 
267 
202 
236 
21'{ I 
220 
176 
180 
155 
128 
156 'Iii 
f 172 " 
135 
106 
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and IX. 
It 1s clearly evldent that the lnhlbl tlon of CO2 re- 11'1: 
lease by tolbutamide is llnear with respect to concentratlon of 
the oral hypoglycemlc agent l while the inhibition by phenethyl-
biguanide is exponential in characterl reachlng a relatively con-
stant level at a concentration of about 8 umoles of agent. Pur-
ther, a conslderably greater inhlbition by phenethylbiguanide is 
evident at all levels of the agents utl1ized. Theae taots indi-
cate that the inhlbltion by the two hypoglycemic agents ls 
brought about by ditterent mechanisms. 
Likewise l the data on the inoorporation of leucine-l-
014 into protein show a remarkable dltterence in the aotion of 
the two chemioala. The inhlbition by tolbutamide is again linear l 
although the experlmental pOints do not dellneate a very exaot 
line. The inhibition by phenethylbiguanide ls ot considerable in-
terest. Little or no etfeot is seen with up to 6 umoles ot the 
oompound added. This is ln agreement with the earlier experimentl 
which showed no inhibition by phenethylbiguanide. (ot. experi-
ments 4,,,5 and 6). However l aa the conoentration ot phenethyl-
biguanide approaohea 8 umoles a very significant drop in incorpo-
ration occurs. This levels out at a concentration of 10 um01es 
and no further change 18 evidenced when 15 umoles of agent are 
added. Thus a considerable lnhlbition oocurs in the range of 8 
umoles ot PEBG. This observation was verified in experlment 10 
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which is given in the appendix in Tables XXIV and XXV. 
One possible explanation for this phenomenon is that 1'1: 
there is some substance present in the incubation mixture which 
ties up the phenethylbiguanide so that it cannot inhibit protein 
synthesis. According to this view, once 8 umoles of phenethyl-
biguanide are present, all of the unknown substance is tied up 
and the excess phenethylbiguanide is free to act as an inhib1tor. 
Thus if the hypothetical inactivating compound were absent entire 
ly, even a small amount of PBBG would inhibit protein incorpora-
tion almost completely. 
Since the most obvious effect of phenethylbiguanide is 
a lowering of blood sugar, it was postulated that the PEBG com-
bined with glucose to give a product which would not affect pro-
tein syntheSis. Once all the glucose in the medium was utilized, 
the free phenethylbiguanide could create its effect. Since the 
total amount of glucose added to each flask in the premix was 8 
umoles, this seemed to be a reasonable postulate. The amounts 
used were such that PEBG and glucose could react in a stoichio-
metric 1:1 relat10nship to form an inactive PEBG-glucose complex. 
The next experiment was designed to test this hypothesis. 
Experiment 12: ~ Effect £! Glucose ~ Inhibition ~ Hypoglycemi< 
Aients ~ Leucine Anabolism ~ Catabolism. 
The following mixtures were incubated~ in duplicate~ 
under the usual conditions: 
control- no glucose; no additive 
control plus glucose- contained glucose; no additive 
tolbutamide- no glucose; tolbutamide added 
tolbutamide plus glucose 
phenethylbiguanide- no glucose; PESO added 
phenethylbiguanide plus glucose 
The premix was prepared as usual~ except that no glu-
cose was added; instead, 8 umoles were added separately to those 
flasks requiring glucose. The concentration of hypoglycemic 
agent was 4 umoles/ml. Each flask contained 0.5 mI. of premix, 
0.5 mI. of homogenate, and 2 uc. of leuc1ne- C14 (U.L.). Results 
appear 1n Tables XX and XXI. 
It 1s 1mmediately obv10us from the data that the pres-
ence of glucose affects ne1ther CO2 release nor incorporation 
into protein. All results obtained with added glucose are essen-
tially the same as those seen in the absence of glucose. 
TABLE XX 
EPFEC'l' or GLUCOSE AND ORAL 
HYPOGLYCEMIC AGENTS ON 01402 RELEASB 
Inoubation 
control 
oontrol 
control - gluoose 
control - glucose 
tolbutamide 
tolbutamide 
tolbutamide 
- glucose 
tolbutamide - glucose 
phenethylblguanlde 
phenethylbiguanide 
PEB(} - gluoose 
Weight 
BaC03 
mg. 
11.5 
13.1 
9.7 
9.2 
9.8 
10.0 
7.7 
10. '7 
8.6 
8.3 
8.1 
Counts 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
lOOK 
Time 
(min) 
13.46 
14.26 
13.21 
11.89 
15.22 
15.06 
15.00 
17.01 
32.69 
29.53 
31.05 
88 
opm opm 
oorr. 
'7429 12 .. 592 
7013 12 .. '751 
7510 12 .. 159 
8410 12 .. 938 
65 r(0 10,429 
6640 10,540 
6666 9,523 
5819 9,638 
3059 4 .. 566 
3386 4 .. 979 
3221 4,737 
TABLE XXI 
EPli'ECT OF GLUCOSE AND ORAL HYPOGLYCEMIC AGENTS 
ON INCORPORATION OF LEUClNE-C14 INTO PROTEIN 
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Weight 
Protein 
mg. 
Counts Time 
(min) 
cpm cpm/mg 
Incubation 
control 6.90 30K 13.31 2254 32'7 
control 6.40 30K 14.08 2131 333 
control - glucose l.lO 30K 12.02 2496 352 
control - glucose 6.65 30K 11.50 2609 392 
tolbutamide 6.90 30K 18.86 1591 231 
tolbutamide '7.10 30K 18.55 1617 228 
tolbutamide - glucose 6.85 30K ll.5'7 1707 249 
tolbutamide - glucose 6.90· 30K 21.68 1384 201 
phenethylbiguanlde 6.90 30K 15.86 1892 274 
phenethylbiguanide 6.45 30K 14.61 2045 31'7 
PEBG - glucose 1.51 30K 15.7'7 1902 254 
PEBO - glucose 7.10 30K 13.12 228'7 322 
go 
SUMMARY AND CONCLUSIONS: 
The action ot the hypoglycemic compounds, tolbutamide 
and phenethylbiguanide, on protein biosynthesis was investigated 
by the use ot rat liver homogenates, the necessary cofactors and 
leucine-cl4• The results show that the incorporation of leucine-
Cl4 into hepatiC protein is inhibited by both compounds, though 
in a strikingly different manner. The inhibition by tolbutamide 
is linear with respect to concentration whereas the inhibition by 
phenethylbiguanide is not evident until a certain concentration 
is reached. At this point, the amount of incorporation decreases 
markedly until it levels off at a very low value. It has been 
postulated that there is some substance present which combines 
with phenethylbiguanide and renders it inactive toward inhibition 
of protein syntheSiS. Glucose was investigated in this respect 
and found to have no effect on either tolbutamide or phenethyl-
biguanide induced inhibition. 
The catabolism of leucine was measured by the amount of 
cl402 liberated in the course of the incubation. Both tolbutamid 
and phenethylbiguanide were found to inhibit CO2 production. 
Again, inhibition by tolbutamide was linear with respect to con-
centration. Phenethylbiguanide caused a pronounced initial inhi-
bition which tended to level off near the same concentration where 
the protein inhibition first occurs. This suggests that one of 
I 
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the reasons that low concentrations of PEBa does not inhibit pro-
tein incorporation is due to the great decrease in leucine catab-
olism. Since less leucine is broken down (catabolized), there is 
necessarily more present to be incorporated into the protein. 
According to this postulation, the initial great decrease in leu-
cine catabolism compensates for the inhibition in protein anabo-
lism. Once the inhibition of protein catabolism has levelled off 
the inhibition of incorporation by added PEBG becomes evident. 
The results found are exactly opposite those reported 
by Krahl (74) fol' insulin. Whereas tolbutamide and phenethyl-
biguanlde inhibit protein synthesis ~ vitro, insulin accelerates 
it. Moreover, while the accelerating action of insulin is depen-
dent on the presence of glucose in the medium; the inhibitory ac. 
tion of the oral hypoglycemic agents is totally unresponsive to 
the addition of glucose. 
These results suggest that the oral hypoglycemic agents 
studied, although very proficient at lowering blood sugar, do not 
possess all the other attributes of insulin. They cannot aid the 
negative protein balance associated with diabetes; they may, in 
fact, due to their inhibitory effects, aggravate the condition. 
I~ 
::ill' 
APPENDIX 
TABLE XXII 
EFFICACY OF WASHINGS 
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All the washings of' the beta-lipoprotein fraction 
were saved. A 1.0 ml. aliquot of each was plated 
and counted. 
Washing (procedure) 
supernatant 
NaCl- MgCl 
reprecipitation 1 
reprecipitation 2 
reprecipitation 3 
TCA 1 
TCA 2 
ethanol 1 
ethanol 2 
ethanol 3 
acetone 1 
acetone 2 
acetone 3 
benzene 
background 
Counts 
30K 
10K 
lK 
lK 
lK 
lK 
lK 
lK 
1K 
1K 
lK 
1K 
lK 
lK 
lK 
Time 
(min. ) 
0.47 
1.95 
3.92 
25.39 
25.03 
60.81 
63.86 
36.02 
53.95 
67.49 
61.60 
58.81 
45.96 
53.90 
53.81 
cpm 
64,000 
5,120 
254 
39 
40 
16 
16 
28 
19 
15 
16 
17 
22 
19 
19 
After the first ethanol wash, essentIally a 
background count is found 1n the supernatant. 
Volume 
of 
Wash(ml. ) 
15.5 
r .0 
7.2 
'7.2 
7.2 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
TABLE XXIII 
EFFICACY OF WASHINGS 
All the washings of the protein fraction were 
saved. A 1.0 ml. aliquot of each washing was 
plated and counted. 
Washing Counts 
Time 
(min. ) cpm 
supernatant 
TCA 
ethanol 1 
ethanol 2 
ethanol 3 
acetone 1 
acetone 2 
acetone 3 
30K 1.09 27,500 
10K 2.13 4,700 
3K 2.89 346 
lK 6.,(4 Itt9 
lK 33.98 29 
lK 59.95 17 
571 39.48 14 
500 30.1"( 18 
After the third ethanol waSh, a background 
count is obtained. This indicates that the 
washings employed were sufficient to remove 
nonincorporated radioactivity. 
93 
Volume 
of 
Wash(ml.) 
6.2 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
TABLE XXIV 
EFFECT OF CONCENTRATION 0' PHENETHYLBIGUANIDE 
ON C1402 RELEASE (Experiment 10) 
Umoles of weifht Counts Time cpm 
PEBG added BaC03 mg.) (min) 
a 16.8 lOOK 3.17 31,500 
0 12.8 lOOK 2."{8 36,000 
2 10.9 lOOK 3.73 26.)800 
2 7.5 lOOK 3.41 28,800 
4 13.5 lOOK 5.38 18,,600 
4 10.9 lOOK 5.04 19,800 
6 9.9 lOOK 6.03 16,600 
r- 6.3 lOOK 4.85 20,600 0 
8 10.3 lOOK ~" 54 ,). 18~ 100 
8 12.4 lOOK 7.14 14,000 
10 11.4 lOOK "7.21 13,900 
10 1'.6 lOOK '(.84 12,800 
15 10.0 lOOK 9.31 10,700 
15 10.8 lOOI\. 9.8;; 10,200 
91.1 
cpm 
corr. 
(7) '700 
(5,,900 
50" "700 
47,,100 
37,700 
36,,300 
28 .. 600 
30,800 
31,,800 
26,300 
25,,200 
19,,500 
17,900 
1'7,,600 
I I 
I 
II 
'.i.I:"1 I.' I I' 
','II 
MI',I 
'1'·1 
" 
!I, 
"li';1 
1'1 I'! 
TABLE XXV 
EFFECT OF CONCENTRATION OF FHENETHYLBIGUANIDE ON 
INCOIU'ORATION OF LEUClNE-1-C14 INTO 
PROTEIN OF RAT LIv"ER (Experiment 10). 
Umoles of 
PBBG added 
Weight 
Protein mg. 
CO'unts Time 
(min) 
cpm 
0 '7.30 10K 5.'78 1730 
0 7.00 10K 3.75 266'7 
2 7.30 10K 5.52 1812 
2 7.15 10K 5.50 1818 
4 7.00 10K 6.19 1616 
4 '( .40 10K 6.32 1582 
6 1.30 10K 6.62 1511 
6 7.15 10K 5. T{ 1'733 
8 7.25 10K 8.31 1203 
8 l.10 10K 9.91 1009 
10 6.90 10K 11.54 86'7 
10 7.30 10K 14.51 689 
15 '{ .10 5K 11.12 450 
15 '7.05 3K ( .13 421 
95 
cpmjlng 
23·7 
381 
248 
254 
231 
214 
201 
242 
166 
142 
126 
94 
63 
60 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
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